{ "$schema_version": "5.3", "review_mode": "fresh", "claim_restatement": { "index_wording": "Systemic menopausal hormone therapy causes a reduction in bothersome vasomotor symptoms in perimenopausal and postmenopausal women.", "entry_form": "claim", "gradeable_restatement": "Systemic menopausal hormone therapy causes a reduction in bothersome vasomotor symptoms in perimenopausal and postmenopausal women.", "restatement_required": true, "split_into": [], "parent_claim": null, "scope_qualifiers": [ { "qualifier": "Menopause stage, symptom burden, age, time since menopause, uterus/oophorectomy status, concurrent hormones, dose, route, baseline HSDD or cognitive status and endpoint horizon are available before outcome measurement; no responder-defined scope.", "determinable_before_outcome": true, "determined_from": "Enrollment and experimental design, before results; no responder-defined scope.", "action": "retained" } ] }, "hypothesis": { "name": "Menopause Hormones: Symptoms, Prevention and Testosterone", "central_claim": "Systemic menopausal hormone therapy causes a reduction in bothersome vasomotor symptoms in perimenopausal and postmenopausal women.", "proposed_mechanism": "Systemic menopausal hormone therapy causes a reduction in bothersome vasomotor symptoms in perimenopausal and postmenopausal women.", "claimed_scope": "Perimenopausal and postmenopausal women with bothersome vasomotor symptoms at enrollment, systemic formulation/route and 4–24-week symptom horizon specified. Chronic disease prevention, diagnosed HSDD and general testosterone enhancement are separately assessed, with baseline age, time since menopause, uterus status and risk fixed before outcomes.", "claimed_level": [ "response", "maintenance" ], "is_conjunctive": false, "conjunctive_note": "The nominal is the clinical sufficiency proposition represented by SC2. Mechanism, superiority, additional indication and safety subclaims are separately reported and do not gate the registered efficacy claim. The original topic family and this narrower gradeable restatement are retained; no response-based exclusions are allowed." }, "rubric_routing": { "primary_rubric": "06-metabolism-aging.md", "secondary_rubrics": [ "07-psychiatry-neuromodulation.md" ], "index_notes_applied": [ "The nominal is the clinical sufficiency proposition represented by SC2. Mechanism, superiority, additional indication and safety subclaims are separately reported and do not gate the registered efficacy claim. The original topic family and this narrower gradeable restatement are retained; no response-based exclusions are allowed." ], "rubric_fit_note": "The frozen seven rubrics have no dedicated menopause or endocrine-treatment rubric. Rubric06 is routed for endocrine physiology and functional clinical outcomes, and rubric07 supplies subjective-endpoint/comparator safeguards. Literal lifespan criteria are quoted unchanged but do not describe this non-lifespan claim. The preregistered adaptation substitutes measured vasomotor symptom frequency/severity and interference for aging trajectories; active hallucination-matched controls are not required for an intervention without unmistakable acute hallucinogenic effects. This limits cross-topic comparability and is not a change to the frozen ladder or universal caps." }, "subclaim_matrix": { "subclaims": [ { "id": "SC1", "statement": "Sex-steroid withdrawal contributes causally to menopausal thermoregulatory symptoms.", "subclaim_type": "mechanism", "scope": "Baseline menopause stage, ovarian function, formulation and symptom phenotype fixed", "claimed_scope": "Baseline menopause stage, ovarian function, formulation and symptom phenotype fixed", "governing_rubric": "06-metabolism-aging.md", "key_evidence_anchor": "Hormonal withdrawal/challenge and thermoregulatory circuit tests", "hsef_level": "Ζ", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Hormone suppression and replacement, a predicted thermoregulatory response under randomized estradiol and mechanistically distinct NKB challenge/blockade support a causal endocrine–thermoregulatory contribution. Deficiency alone does not predict all symptoms; objective pathway tests and symptomatic/asymptomatic comparisons preserve this boundary. Ζ is contribution, not sole-cause necessity.", "rubric_adaptation": "Controlled endocrine suppression/restoration and independently measured thermoregulatory challenge responses test a causal contribution of sex-steroid withdrawal. NK3 challenge/blockade narrows downstream circuitry but is not by itself proof steroid withdrawal is necessary or sufficient for every flush. Objective heat-dissipation events distinguish physiology from a hormone concentration proxy." }, { "id": "SC2", "statement": "Systemic menopausal hormone therapy reduces bothersome vasomotor symptoms versus a credible comparator.", "subclaim_type": "sufficiency", "scope": "Perimenopausal/postmenopausal women with symptoms at baseline; route, regimen and 4–24-week symptom horizon specified", "claimed_scope": "Perimenopausal/postmenopausal women with symptoms at baseline; route, regimen and 4–24-week symptom horizon specified", "governing_rubric": "06-metabolism-aging.md", "key_evidence_anchor": "Controlled hot-flush frequency/severity and placebo response", "hsef_level": "Ζ", "confidence": "High", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Repeated blinded hormone trials show symptom relief beyond placebo in baseline symptomatic women, including oral and transdermal regimens. MsFLASH provides an active nonhormonal comparison; objective sweating-threshold/flush experiments reduce a reporting-only explanation, and withdrawal observations agree with reversible control. Ζ reflects complementary failure structures; replication/report counts alone do not provide independence. Η would require stronger mediator isolation and prospective cross-context control of major exceptions.", "rubric_adaptation": "For the registered therapeutic proposition, blinded randomized systemic hormone treatment versus credible placebo or a nonhormonal active arm, with enrollment symptoms and measured subsequent symptom frequency/severity, is the human clinical equivalent. This is meaningful symptom function within a fixed horizon, not lifespan extension; hormone level changes alone do not qualify. Clinical diary trials are replicated one pharmacological line, while a predicted sweat-threshold/physiological-flush response measured independently of diaries narrows a specific reporting-error alternative." }, { "id": "SC3", "statement": "Menopausal hormone therapy provides net long-term prevention of cardiovascular or neurodegenerative disease.", "subclaim_type": "generalization", "scope": "Age, time since menopause, uterus status, formulation, route and baseline disease risk defined before outcomes", "claimed_scope": "Age, time since menopause, uterus status, formulation, route and baseline disease risk defined before outcomes", "governing_rubric": "06-metabolism-aging.md", "key_evidence_anchor": "Hard disease endpoints; symptom efficacy does not confer prevention or all-regimen safety", "hsef_level": "Β", "confidence": "High", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Net cardiovascular or neurodegenerative prevention does not inherit symptom efficacy. WHI/WHIMS and WISDOM supply direct regimen/age-specific clinical contradictions, while early ELITE CIMT and Medicare associations leave a narrower preventive possibility open. Positive surrogate/observational support is insufficient for hard prevention; the functional contradiction downgrades that supportive Γ-level route to Β. It is not a blanket claim all formulations or early symptomatic use are harmful.", "rubric_adaptation": "The claimed net prevention requires incident cardiovascular disease, dementia and integrated clinically important benefits/harms over years. CIMT, metabolic markers, cognitive test performance and symptom relief are not interchangeable with prevention of these diseases. Negative randomized clinical endpoints are informative discriminators but never positive threshold crossings." }, { "id": "SC4", "statement": "Testosterone improves sexual desire/function in postmenopausal women with baseline hypoactive sexual desire disorder.", "subclaim_type": "sufficiency", "scope": "HSDD diagnosed before treatment; measured physiologic-dose formulation and concomitant hormones specified", "claimed_scope": "HSDD diagnosed before treatment; measured physiologic-dose formulation and concomitant hormones specified", "governing_rubric": "06-metabolism-aging.md", "key_evidence_anchor": "Controlled sexual-function endpoints and duration-specific safety", "hsef_level": "Ε", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Testosterone patch trials establish a modest causal sexual-function benefit in baseline diagnosed postmenopausal HSDD, with limits across dose, concurrent estrogen and endpoints. These replicated, closely related intervention platforms do not supply a separate orthogonal causal mechanism or all-women indication; Ε preserves the mapped clinical context and finite safety horizon.", "rubric_adaptation": "Blinded randomized testosterone allocation with baseline diagnosed HSDD, measured desire, distress and satisfying sexual function tests this indication. The subjective clinical phenotype is the stated endpoint; blood testosterone is target engagement rather than efficacy. Trials using the same patch and sexual diary platform form a replicated line, not several mechanistically independent modalities." }, { "id": "SC5", "statement": "Testosterone benefits generalize to cognition, energy and muscle outcomes in women without HSDD.", "subclaim_type": "generalization", "scope": "Baseline indication, age, sex-steroid exposure, dose and outcome specified; sexual-function benefit does not transfer", "claimed_scope": "Baseline indication, age, sex-steroid exposure, dose and outcome specified; sexual-function benefit does not transfer", "governing_rubric": "06-metabolism-aging.md", "key_evidence_anchor": "Original nonspecific wellbeing/cognition/muscle trials and negative controls", "hsef_level": "Γ", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "One verbal-learning outcome and high-exposure muscle/performance signals provide narrower clinical positives; these are retained with their doses and populations. They do not establish the bundled general cognition, energy and muscle proposition in women without HSDD. Multiple cognitive domains and wellbeing/fatigue outcomes are null. The full enhancement proposition retains partial support at Γ; this does not deny the separate HSDD clinical efficacy or the isolated task finding.", "rubric_adaptation": "Specific cognitive tasks, measured muscle performance and patient-important energy/function must be kept separate. A task-specific benefit in a controlled trial and muscle effects at supraphysiologic doses establish bounded contexts, not generalized wellbeing at physiological replacement doses. No positive HSDD result is inherited by nonspecific domains." } ], "aggregation_rule": "primary-subclaim", "aggregation_preregistered": true, "aggregation_rationale": "The nominal is the clinical sufficiency proposition represented by SC2. Mechanism, superiority, additional indication and safety subclaims are separately reported and do not gate the registered efficacy claim. The original topic family and this narrower gradeable restatement are retained; no response-based exclusions are allowed.", "primary_subclaim_id": "SC2", "aggregation_derivation": "The registered primary-subclaim rule assigns Ζ with High confidence from SC2: systemic menopausal hormone therapy causes vasomotor symptom relief in baseline symptomatic women. Endocrine–thermoregulatory contribution is separately rated Ζ, prevention Β, testosterone for HSDD Ε, and broader testosterone enhancement Γ. Weakest-link would return Β for an unregistered conjunction of these different indications; primary-subclaim and scope-matched return Ζ. The symptom grade does not establish preventive or testosterone efficacy.", "aggregation_alternatives": { "weakest_link_would_return": "Β", "primary_subclaim_would_return": "Ζ", "scope_matched_would_return": "Ζ", "note": "Separate narrow successes do not replace the preregistered full-scope gate." }, "index_rule_deviation": "" }, "competing_models": { "models_evaluated": [ { "rank_in_tournament": 1, "model_id": "M1", "is_nominal": true, "name": "Sex-steroid replacement reduces hormone-withdrawal symptoms", "core_claim": "Replacing sex-steroid signaling reduces vasomotor symptoms in enrolled symptomatic women.", "explains_what_nominal_does_not": "Replacing sex-steroid signaling reduces vasomotor symptoms in enrolled symptomatic women.", "strongest_supporting_evidence": [ "Placebo-controlled oral/transdermal trials, an objective sweating-threshold prediction and concordant withdrawal observations favor real biological symptom control." ], "strongest_contradictory_evidence": [ "Variable response, symptom-free low-estrogen women and nonhormonal efficacy defeat sole-cause/necessity claims; symptom relief does not establish prevention." ], "hsef_level_for_this_model": "Ζ", "rationale": "Placebo-controlled oral/transdermal trials, an objective sweating-threshold prediction and concordant withdrawal observations favor real biological symptom control. Variable response, symptom-free low-estrogen women and nonhormonal efficacy defeat sole-cause/necessity claims; symptom relief does not establish prevention." }, { "rank_in_tournament": 2, "model_id": "M2", "is_nominal": false, "name": "Nonhormonal thermoregulatory pathway modulation", "core_claim": "NK3 and related thermoregulatory interventions relieve the same vasomotor phenotype without systemic hormone replacement.", "explains_what_nominal_does_not": "NK3 and related thermoregulatory interventions relieve the same vasomotor phenotype without systemic hormone replacement.", "strongest_supporting_evidence": [ "NKB blinded challenge and NK3 antagonist controlled trials connect pathway perturbation to objective flushing and clinical symptoms; OASIS3 adds a distinct dual-neurokinin intervention." ], "strongest_contradictory_evidence": [ "MOONLIGHTI was null at its tested dose/context, liver and other adverse outcomes require separate assessment, and the full hormone–KNDy mediator chain remains unisolated." ], "hsef_level_for_this_model": "Ζ", "rationale": "NKB blinded challenge and NK3 antagonist controlled trials connect pathway perturbation to objective flushing and clinical symptoms; OASIS3 adds a distinct dual-neurokinin intervention. MOONLIGHTI was null at its tested dose/context, liver and other adverse outcomes require separate assessment, and the full hormone–KNDy mediator chain remains unisolated." }, { "rank_in_tournament": 3, "model_id": "M4", "is_nominal": false, "name": "Tissue, receptor and route effects separate indications", "core_claim": "Hormone effects depend on tissue, regimen and baseline context, allowing symptom benefit alongside different vascular, cognitive and sexual effects.", "explains_what_nominal_does_not": "Hormone effects depend on tissue, regimen and baseline context, allowing symptom benefit alongside different vascular, cognitive and sexual effects.", "strongest_supporting_evidence": [ "WHI separate regimens, ELITE timing-dependent CIMT and testosterone domain/dose trials demonstrate mapped endpoint/context differences." ], "strongest_contradictory_evidence": [ "These contrasts do not identify every mediator, and a unified model cannot claim prospective risk prediction for every modern formulation." ], "hsef_level_for_this_model": "Ε", "rationale": "WHI separate regimens, ELITE timing-dependent CIMT and testosterone domain/dose trials demonstrate mapped endpoint/context differences. These contrasts do not identify every mediator, and a unified model cannot claim prospective risk prediction for every modern formulation." }, { "rank_in_tournament": 4, "model_id": "M3", "is_nominal": false, "name": "Expectancy and spontaneous fluctuation", "core_claim": "Placebo response, regression and natural symptom fluctuation explain part of apparent improvement.", "explains_what_nominal_does_not": "Placebo response, regression and natural symptom fluctuation explain part of apparent improvement.", "strongest_supporting_evidence": [ "Substantial placebo changes in MsFLASH and modern trials, attenuated KEEPS group differences and uncontrolled clinic cohorts support this contribution." ], "strongest_contradictory_evidence": [ "Randomized active-treatment differences and objective physiological effects contradict an exclusive reporting-only account; placebo-arm change does not itself randomize expectancy versus natural recovery." ], "hsef_level_for_this_model": "Β", "rationale": "Substantial placebo changes in MsFLASH and modern trials, attenuated KEEPS group differences and uncontrolled clinic cohorts support this contribution. Randomized active-treatment differences and objective physiological effects contradict an exclusive reporting-only account; placebo-arm change does not itself randomize expectancy versus natural recovery." } ], "tournament_summary": "Descriptive comparison; does not modify the nominal score. MsFLASH PMID24861828 shows estradiol and the nonhormonal venlafaxine both outperform placebo, with an imprecise active-treatment difference. It distinguishes genuine pathway-sensitive relief from an exclusive nonspecific account; it does not prove hormone replacement is universally superior to NK3 antagonism. The first two models are compatible therapeutic accounts, and their ordering follows the registered MHT claim rather than an unperformed direct hormone-versus-NK3 trial.", "study_separating_rank1_from_rank2": "MsFLASH PMID24861828 shows estradiol and the nonhormonal venlafaxine both outperform placebo, with an imprecise active-treatment difference. It distinguishes genuine pathway-sensitive relief from an exclusive nonspecific account; it does not prove hormone replacement is universally superior to NK3 antagonism. The first two models are compatible therapeutic accounts, and their ordering follows the registered MHT claim rather than an unperformed direct hormone-versus-NK3 trial.", "nominal_wins_only_by_funding_artifact": false, "level_unchanged_by_tournament": true }, "evidence_inventory": [ { "n": 1, "pmid": "39317030", "title": "Ultra-low dose estradiol and dydrogesterone for the treatment of menopausal symptoms in a pooled, multi-ethnic population.", "citation": "Stevenson JC, Ren M, Kahler E et al. Ultra-low dose estradiol and dydrogesterone for the treatment of menopausal symptoms in a pooled, multi-ethnic population. Maturitas. 2024.", "doi": "10.1016/j.maturitas.2024.108117", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/39317030/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39317030/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "UltraLow-E2Dydrogesterone-China-CTR20160689", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2" ], "favors_models": [ "M1", "M4" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "A pooled Europe/China randomized dataset shows fewer hot flushes with ultra-low estradiol/dydrogesterone than placebo.", "what_it_does_not_show": "Pooled report includes the Chinese parent trial; not an independent new intervention or long-term safety test.", "confounders_present": [ "Pooled report includes the Chinese parent trial; not an independent new intervention or long-term safety test." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [ "UltraLow-E2Dydrogesterone-China-CTR20160689", "European ultra-low E2/dydrogesterone trial" ] }, { "n": 2, "pmid": "10993030", "title": "Suppression of vasomotor and vulvovaginal symptoms with continuous oral 17beta-estradiol.", "citation": "Notelovitz M, Mattox JH. Suppression of vasomotor and vulvovaginal symptoms with continuous oral 17beta-estradiol. Menopause (New York, N.Y.). 2000.", "doi": "10.1097/00042192-200007050-00005", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/10993030/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/10993030/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID10993030", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2" ], "favors_models": [ "M1", "M4" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Randomized oral estradiol at two doses reduced hot-flush frequency compared with placebo over twelve weeks.", "what_it_does_not_show": "Selected clinical trial populations and short follow-up do not establish cardiovascular or dementia prevention.", "confounders_present": [ "Selected clinical trial populations and short follow-up do not establish cardiovascular or dementia prevention." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 3, "pmid": "16735941", "title": "Efficacy of a new, oral estradiol acetate formulation for relief of menopause symptoms.", "citation": "Speroff L, Haney AF, Gilbert RD et al. Efficacy of a new, oral estradiol acetate formulation for relief of menopause symptoms. Menopause (New York, N.Y.). 2006.", "doi": "10.1097/01.gme.0000182802.06762.b2", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/16735941/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/16735941/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID16735941", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2" ], "favors_models": [ "M1", "M4" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Two placebo-controlled oral estradiol acetate trials show dose-dependent timing and magnitude of symptom relief.", "what_it_does_not_show": "Two trials share formulation and diary instruments; higher dose does not prove all-regimen superiority or safety.", "confounders_present": [ "Two trials share formulation and diary instruments; higher dose does not prove all-regimen superiority or safety." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 4, "pmid": "34402360", "title": "Ultra-low-dose estradiol and dydrogesterone: a phase III study for vasomotor symptoms in China.", "citation": "Ren M, Ruan X, Gu L et al. Ultra-low-dose estradiol and dydrogesterone: a phase III study for vasomotor symptoms in China. Climacteric : the journal of the International Menopause Society. 2022.", "doi": "10.1080/13697137.2021.1956894", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/34402360/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34402360/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "UltraLow-E2Dydrogesterone-China-CTR20160689", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2" ], "favors_models": [ "M1", "M4" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "A Chinese randomized trial shows ultra-low estradiol/dydrogesterone reduces daily hot flushes more than placebo.", "what_it_does_not_show": "Placebo improved substantially; twelve-week symptom benefit is not disease prevention.", "confounders_present": [ "Placebo improved substantially; twelve-week symptom benefit is not disease prevention." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 5, "pmid": "9840563", "title": "Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial.", "citation": "Greendale GA, Reboussin BA, Hogan P et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstetrics and gynecology. 1998.", "doi": "10.1016/s0029-7844(98)00305-6", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/9840563/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/9840563/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID9840563", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [ "M1", "M4" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "PEPI hormone regimens reduce vasomotor symptoms while anxiety, cognitive and affective checklist outcomes show no treatment difference.", "what_it_does_not_show": "Multiple hormone regimens belong to one parent trial and symptom instruments cannot establish dementia prevention.", "confounders_present": [ "Multiple hormone regimens belong to one parent trial and symptom instruments cannot establish dementia prevention." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 6, "pmid": "3928674", "title": "Treatment of hot flashes with transdermal estradiol administration.", "citation": "Steingold KA, Laufer L, Chetkowski RJ et al. Treatment of hot flashes with transdermal estradiol administration. The Journal of clinical endocrinology and metabolism. 1985.", "doi": "10.1210/jcem-61-4-627", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/3928674/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/3928674/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID3928674", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [ "M1", "M4" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Randomized transdermal estradiol produced exposure-dependent hot-flush suppression at tested doses.", "what_it_does_not_show": "Small early trial and regression predictions are not validated individual response thresholds or long-term safety evidence.", "confounders_present": [ "Small early trial and regression predictions are not validated individual response thresholds or long-term safety evidence." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 7, "pmid": "30489424", "title": "Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms.", "citation": "Simon JA, Kaunitz AM, Kroll R et al. Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms. Menopause (New York, N.Y.). 2019.", "doi": "10.1097/GME.0000000000001271", "pmcid": "PMC6493699", "url": "https://pubmed.ncbi.nlm.nih.gov/30489424/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/30489424/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "REPLENISH-NCT01942668", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2" ], "favors_models": [ "M1", "M4" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "REPLENISH participants reported improved menopause-specific quality of life and vasomotor domain scores with several oral estradiol/progesterone doses.", "what_it_does_not_show": "Secondary outcomes and correlations do not prove mediation; this is the same parent trial as its sleep report.", "confounders_present": [ "Secondary outcomes and correlations do not prove mediation; this is the same parent trial as its sleep report." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 8, "pmid": "30586005", "title": "Improvement in sleep outcomes with a 17β-estradiol-progesterone oral capsule (TX-001HR) for postmenopausal women.", "citation": "Kagan R, Constantine G, Kaunitz AM et al. Improvement in sleep outcomes with a 17β-estradiol-progesterone oral capsule (TX-001HR) for postmenopausal women. Menopause (New York, N.Y.). 2018.", "doi": "10.1097/GME.0000000000001278", "pmcid": "PMC6553506", "url": "https://pubmed.ncbi.nlm.nih.gov/30586005/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/30586005/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "REPLENISH-NCT01942668", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2" ], "favors_models": [ "M1", "M4" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "REPLENISH oral estradiol/progesterone improved several self-reported sleep outcomes compared with placebo.", "what_it_does_not_show": "Sleep was secondary and subjective; improvements do not establish all sleep disorders are hormone mediated.", "confounders_present": [ "Sleep was secondary and subjective; improvements do not establish all sleep disorders are hormone mediated." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 9, "pmid": "12642637", "title": "Effects of estrogen plus progestin on health-related quality of life.", "citation": "Hays J, Ockene JK, Brunner RL et al. Effects of estrogen plus progestin on health-related quality of life. The New England journal of medicine. 2003.", "doi": "10.1056/NEJMoa030311", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/12642637/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/12642637/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "WHI-EplusP", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [ "M1", "M4" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "WHI combined therapy relieved vasomotor symptoms in younger symptomatic women but did not improve general quality of life meaningfully overall.", "what_it_does_not_show": "Older prevention cohort differs from modern symptom-selected users; several endpoints and subgroups require caution.", "confounders_present": [ "Older prevention cohort differs from modern symptom-selected users; several endpoints and subgroups require caution." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 10, "pmid": "7547766", "title": "Hormone replacement therapy, sleep quality and psychological wellbeing.", "citation": "Purdie DW, Empson JA, Crichton C et al. Hormone replacement therapy, sleep quality and psychological wellbeing. British journal of obstetrics and gynaecology. 1995.", "doi": "10.1111/j.1471-0528.1995.tb11433.x", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/7547766/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/7547766/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID7547766", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2" ], "favors_models": [ "M1", "M4" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "A small single-blind trial improved menopausal symptoms without measured polysomnographic sleep improvement.", "what_it_does_not_show": "Limited size and single blinding constrain inference; symptom relief need not normalize every sleep parameter.", "confounders_present": [ "Limited size and single blinding constrain inference; symptom relief need not normalize every sleep parameter." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 11, "pmid": "27163519", "title": "Conjugated estrogens and bazedoxifene in minority populations: pooled analysis of four phase 3 trials.", "citation": "Pinkerton JV, Pickar JH, Ryan KA et al. Conjugated estrogens and bazedoxifene in minority populations: pooled analysis of four phase 3 trials. Menopause (New York, N.Y.). 2016.", "doi": "10.1097/GME.0000000000000617", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/27163519/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/27163519/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID27163519", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2" ], "favors_models": [ "M1", "M4" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "SMART pooled minority/white subgroup analyses show symptom improvement with conjugated estrogens/bazedoxifene.", "what_it_does_not_show": "Post hoc pooling and modest minority representation do not establish ethnic equivalence or independent replication per report.", "confounders_present": [ "Post hoc pooling and modest minority representation do not establish ethnic equivalence or independent replication per report." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 12, "pmid": "16014592", "title": "Symptom experience after discontinuing use of estrogen plus progestin.", "citation": "Ockene JK, Barad DH, Cochrane BB et al. Symptom experience after discontinuing use of estrogen plus progestin. JAMA. 2005.", "doi": "10.1001/jama.294.2.183", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/16014592/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/16014592/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "WHI-EplusP", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [ "M1", "M4" ], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Former WHI combined-hormone users reported more vasomotor symptoms after study-pill cessation than former placebo users.", "what_it_does_not_show": "Selected continuing users and post-stop unblinding limit causal withdrawal inference and independence from WHI allocation.", "confounders_present": [ "Selected continuing users and post-stop unblinding limit causal withdrawal inference and independence from WHI allocation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 13, "pmid": "18443259", "title": "Persistent hot flushes in older postmenopausal women.", "citation": "Huang AJ, Grady D, Jacoby VL et al. Persistent hot flushes in older postmenopausal women. Archives of internal medicine. 2008.", "doi": "10.1001/archinte.168.8.840", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/18443259/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/18443259/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID18443259", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [ "M1", "M2" ], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "Some older women have persistent hot flushes, associated with baseline clinical factors but not measured estradiol concentration.", "what_it_does_not_show": "Observational associations do not isolate withdrawal causality or identify an outcome-independent hormone responder group.", "confounders_present": [ "Observational associations do not isolate withdrawal causality or identify an outcome-independent hormone responder group." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 14, "pmid": "24084921", "title": "Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.", "citation": "Manson JE, Chlebowski RT, Stefanick ML et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013.", "doi": "10.1001/jama.2013.278040", "pmcid": "PMC3963523", "url": "https://pubmed.ncbi.nlm.nih.gov/24084921/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/24084921/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "WHI-two-parent-trials", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:METHODS:paragraph0, 1:METHODS:paragraph2, 2:RESULTS:paragraph24, 2:RESULTS:paragraph27, 2:RESULTS:paragraph29, 2:RESULTS:paragraph35, 2:RESULTS:paragraph37. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [ "M1", "M4" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "mixed", "what_it_shows": "Extended WHI analyses retain vasomotor benefit but divergent clinical risks and benefits; neither regimen improved overall mortality.", "what_it_does_not_show": "Two parent randomized trials generate many reports; oral CEE regimens cannot be transferred wholesale to other routes or younger indications.", "confounders_present": [ "Two parent randomized trials generate many reports; oral CEE regimens cannot be transferred wholesale to other routes or younger indications." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [ "WHI-EplusP", "WHI-CEEalone" ] }, { "n": 15, "pmid": "40952729", "title": "Menopausal Hormone Therapy and Cardiovascular Diseases in Women With Vasomotor Symptoms: A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trials.", "citation": "Rossouw JE, Aragaki AK, Manson JE et al. Menopausal Hormone Therapy and Cardiovascular Diseases in Women With Vasomotor Symptoms: A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trials. JAMA internal medicine. 2025.", "doi": "10.1001/jamainternmed.2025.4510", "pmcid": "PMC12439186", "url": "https://pubmed.ncbi.nlm.nih.gov/40952729/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40952729/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "ErratumIn: PMID41182785", "ErratumIn: PMID41396618" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "WHI-two-parent-trials", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [ "M1", "M4" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "The WHI symptom/CVD secondary analysis reports age- and regimen-dependent clinical and symptom effects.", "what_it_does_not_show": "Two attached corrections concern text/supplement and Figure 3; quantitative reliance is withheld pending their details, and subgroup analyses are not new trials.", "confounders_present": [ "Two attached corrections concern text/supplement and Figure 3; quantitative reliance is withheld pending their details, and subgroup analyses are not new trials." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [ "WHI-EplusP", "WHI-CEEalone" ] }, { "n": 16, "pmid": "19139363", "title": "Postmenopausal hormone therapy and subclinical cerebrovascular disease: the WHIMS-MRI Study.", "citation": "Coker LH, Hogan PE, Bryan NR et al. Postmenopausal hormone therapy and subclinical cerebrovascular disease: the WHIMS-MRI Study. Neurology. 2009.", "doi": "10.1212/01.wnl.0000339036.88842.9e", "pmcid": "PMC2677498", "url": "https://pubmed.ncbi.nlm.nih.gov/19139363/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/19139363/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "WHI-two-parent-trials", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M4" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "null", "what_it_shows": "WHIMS-MRI found no significant hormone-allocation difference in ischemic lesion volumes despite clinical cognitive concerns.", "what_it_does_not_show": "Post-trial MRI participants were selected; this proxy null neither proves brain protection nor explains every dementia mechanism.", "confounders_present": [ "Post-trial MRI participants were selected; this proxy null neither proves brain protection nor explains every dementia mechanism." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [ "WHI-EplusP", "WHI-CEEalone" ] }, { "n": 17, "pmid": "17626056", "title": "Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women.", "citation": "Vickers MR, MacLennan AH, Lawton B et al. Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ (Clinical research ed.). 2007.", "doi": "10.1136/bmj.39266.425069.AD", "pmcid": "PMC1939792", "url": "https://pubmed.ncbi.nlm.nih.gov/17626056/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/17626056/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID17626056", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M4" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "contradicts", "what_it_shows": "WISDOM found more cardiovascular and thromboembolic events with combined therapy started many years after menopause.", "what_it_does_not_show": "Premature closure and brief follow-up limit cancer, dementia and early-initiation conclusions.", "confounders_present": [ "Premature closure and brief follow-up limit cancer, dementia and early-initiation conclusions." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 18, "pmid": "20166859", "title": "Testosterone treatment of HSDD in naturally menopausal women: the ADORE study.", "citation": "Panay N, Al-Azzawi F, Bouchard C et al. Testosterone treatment of HSDD in naturally menopausal women: the ADORE study. Climacteric : the journal of the International Menopause Society. 2010.", "doi": "10.3109/13697131003675922", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/20166859/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/20166859/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID20166859", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "M4" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "ADORE found improved satisfying sexual events, desire and distress with a testosterone patch in naturally menopausal HSDD women.", "what_it_does_not_show": "Selected diagnosed HSDD and six-month outcomes do not establish general cognition, energy or long-term safety benefit.", "confounders_present": [ "Selected diagnosed HSDD and six-month outcomes do not establish general cognition, energy or long-term safety benefit." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 19, "pmid": "18987368", "title": "Testosterone for low libido in postmenopausal women not taking estrogen.", "citation": "Davis SR, Moreau M, Kroll R et al. Testosterone for low libido in postmenopausal women not taking estrogen. The New England journal of medicine. 2008.", "doi": "10.1056/NEJMoa0707302", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/18987368/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/18987368/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID18987368", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "M4" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "APHRODITE found modest sexual-function benefit at the higher tested testosterone patch dose in postmenopausal HSDD women without estrogen.", "what_it_does_not_show": "Lower dose missed the event-frequency endpoint; androgenic events increased and rare breast outcomes cannot settle long-term risk.", "confounders_present": [ "Lower dose missed the event-frequency endpoint; androgenic events increased and rare breast outcomes cannot settle long-term risk." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 20, "pmid": "15863529", "title": "Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial.", "citation": "Buster JE, Kingsberg SA, Aguirre O et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstetrics and gynecology. 2005.", "doi": "10.1097/01.AOG.0000158103.27672.0d", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/15863529/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/15863529/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "INTIMATE-SM2", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "M4" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "A randomized patch trial improved sexual activity, desire and distress after surgical menopause with concomitant estrogen.", "what_it_does_not_show": "The indicated population and short exposure do not establish nonspecific enhancement or lifelong safety.", "confounders_present": [ "The indicated population and short exposure do not establish nonspecific enhancement or lifelong safety." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 21, "pmid": "16014407", "title": "Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder.", "citation": "Simon J, Braunstein G, Nachtigall L et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. The Journal of clinical endocrinology and metabolism. 2005.", "doi": "10.1210/jc.2004-1747", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/16014407/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/16014407/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "INTIMATE-SM1", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "M4" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "INTIMATE SM1 improved satisfying sexual activity and desire and reduced distress versus placebo after surgical menopause.", "what_it_does_not_show": "Patient-reported endpoints, concurrent estrogen and sponsor-related trial platform constrain mechanistic independence.", "confounders_present": [ "Patient-reported endpoints, concurrent estrogen and sponsor-related trial platform constrain mechanistic independence." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 22, "pmid": "16932240", "title": "Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study.", "citation": "Shifren JL, Davis SR, Moreau M et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. Menopause (New York, N.Y.). 2006.", "doi": "10.1097/01.gme.0000243567.32828.99", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/16932240/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/16932240/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "ErratumIn: PMID not supplied" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID16932240", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "M4" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "INTIMATE NM1 reported improved sexual events, desire and distress in naturally menopausal HSDD women taking estrogen.", "what_it_does_not_show": "An attached erratum is recorded without identifier; baseline SHBG analytic restriction and short follow-up limit inference.", "confounders_present": [ "An attached erratum is recorded without identifier; baseline SHBG analytic restriction and short follow-up limit inference." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 23, "pmid": "21142609", "title": "Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen.", "citation": "Nachtigall L, Casson P, Lucas J et al. Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2011.", "doi": "10.3109/09513590.2010.487597", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/21142609/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/21142609/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "INTIMATE-surgical-pooled-parent-reports", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "M4" ], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Open-label extensions reported no major worsening of common safety measures during testosterone patch exposure.", "what_it_does_not_show": "Selected continuing participants and lack of randomized long-term comparator cannot exclude rare breast or cardiovascular harm.", "confounders_present": [ "Selected continuing participants and lack of randomized long-term comparator cannot exclude rare breast or cardiovascular harm." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [ "INTIMATE-SM1", "INTIMATE-SM2" ] }, { "n": 24, "pmid": "17653960", "title": "A double-blind, randomized, placebo-controlled trial of the effect of testosterone cream on the sexual motivation of menopausal hysterectomized women with hypoactive sexual desire disorder.", "citation": "El-Hage G, Eden JA, Manga RZ. A double-blind, randomized, placebo-controlled trial of the effect of testosterone cream on the sexual motivation of menopausal hysterectomized women with hypoactive sexual desire disorder. Climacteric : the journal of the International Menopause Society. 2007.", "doi": "10.1080/13697130701364644", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/17653960/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/17653960/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID17653960", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4", "SC5" ], "favors_models": [ "M4" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "A testosterone cream crossover trial improved sexual domains in HSDD women but not mood or energy.", "what_it_does_not_show": "Small sample, concurrent estrogen and crossover limitations do not establish broad cognitive or muscle benefit.", "confounders_present": [ "Small sample, concurrent estrogen and crossover limitations do not establish broad cognitive or muscle benefit." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 25, "pmid": "17627745", "title": "Evaluation of the clinical relevance of benefits associated with transdermal testosterone treatment in postmenopausal women with hypoactive sexual desire disorder.", "citation": "Kingsberg S, Shifren J, Wekselman K et al. Evaluation of the clinical relevance of benefits associated with transdermal testosterone treatment in postmenopausal women with hypoactive sexual desire disorder. The journal of sexual medicine. 2007.", "doi": "10.1111/j.1743-6109.2007.00526.x", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/17627745/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/17627745/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "INTIMATE-surgical-pooled-parent-reports", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "M4" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "An interviewed subset of two testosterone trials reported meaningful sexual benefit more often on active patches.", "what_it_does_not_show": "Selected interviews and responder analyses are not an independent trial or a baseline definition of who benefits.", "confounders_present": [ "Selected interviews and responder analyses are not an independent trial or a baseline definition of who benefits." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [ "INTIMATE-SM1", "INTIMATE-SM2" ] }, { "n": 26, "pmid": "16735935", "title": "Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial.", "citation": "Davis SR, van der Mooren MJ, van Lunsen RH et al. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Menopause (New York, N.Y.). 2006.", "doi": "10.1097/01.gme.0000179049.08371.c7", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/16735935/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/16735935/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "ErratumIn: PMID not supplied" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID16735935", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "M4" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "Testosterone patch improved desire with transdermal estrogen after oophorectomy, while the sexual-event endpoint was not significant.", "what_it_does_not_show": "Small sample and incomplete retention limit precision; author-name correction is attached and not a new source.", "confounders_present": [ "Small sample and incomplete retention limit precision; author-name correction is attached and not a new source." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 27, "pmid": "16043675", "title": "Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial.", "citation": "Braunstein GD, Sundwall DA, Katz M et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Archives of internal medicine. 2005.", "doi": "10.1001/archinte.165.14.1582", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/16043675/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/16043675/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID16043675", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "M4" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "A dose-ranging patch trial found sexual-domain benefit at an intermediate dose, with lower-dose nulls and no consistent monotonic response.", "what_it_does_not_show": "Substantial attrition and marginal endpoint significance weaken precise dose-response prediction.", "confounders_present": [ "Substantial attrition and marginal endpoint significance weaken precise dose-response prediction." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 28, "pmid": "39283522", "title": "Effect of transdermal testosterone therapy on mood and cognitive symptoms in peri- and postmenopausal women: a pilot study.", "citation": "Glynne S, Kamal A, Kamel AM et al. Effect of transdermal testosterone therapy on mood and cognitive symptoms in peri- and postmenopausal women: a pilot study. Archives of women's mental health. 2025.", "doi": "10.1007/s00737-024-01513-6", "pmcid": "PMC12092509", "url": "https://pubmed.ncbi.nlm.nih.gov/39283522/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39283522/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID39283522", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC5" ], "favors_models": [ "M4" ], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "A retrospective menopause-clinic cohort reported mood and cognitive symptom improvement after testosterone addition.", "what_it_does_not_show": "No randomized comparator; expectation, regression, concurrent HRT and selective treatment seeking prevent causal generalization.", "confounders_present": [ "No randomized comparator; expectation, regression, concurrent HRT and selective treatment seeking prevent causal generalization." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 29, "pmid": "23095007", "title": "Effect of estrogen and testosterone replacement therapy on cognitive fatigue.", "citation": "Möller MC, Rådestad AF, von Schoultz B et al. Effect of estrogen and testosterone replacement therapy on cognitive fatigue. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2013.", "doi": "10.3109/09513590.2012.730568", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/23095007/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/23095007/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "Testosterone-estrogen-oophorectomy-50women", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC5" ], "favors_models": [ "M4" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "null", "what_it_shows": "A surgical-menopause crossover trial found no cognitive-fatigue benefit from testosterone added to estrogen.", "what_it_does_not_show": "Small sample and a specific oral regimen cannot exclude every formulation effect; same parent as memory analysis.", "confounders_present": [ "Small sample and a specific oral regimen cannot exclude every formulation effect; same parent as memory analysis." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 30, "pmid": "20555288", "title": "Effects of testosterone and estrogen replacement on memory function.", "citation": "Möller MC, Bartfai AB, Rådestad AF. Effects of testosterone and estrogen replacement on memory function. Menopause (New York, N.Y.). 2010.", "doi": "10.1097/gme.0b013e3181dc2e40", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/20555288/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/20555288/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "Testosterone-estrogen-oophorectomy-50women", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC5" ], "favors_models": [ "M4" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "contradicts", "what_it_shows": "Testosterone added to estrogen worsened immediate verbal memory while other memory outcomes were unaffected.", "what_it_does_not_show": "Small surgical-menopause trial and multiple domains do not prove all testosterone regimens impair cognition.", "confounders_present": [ "Small surgical-menopause trial and multiple domains do not prove all testosterone regimens impair cognition." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 31, "pmid": "24716847", "title": "Transdermal testosterone improves verbal learning and memory in postmenopausal women not on oestrogen therapy.", "citation": "Davis SR, Jane F, Robinson PJ et al. Transdermal testosterone improves verbal learning and memory in postmenopausal women not on oestrogen therapy. Clinical endocrinology. 2014.", "doi": "10.1111/cen.12459", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/24716847/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/24716847/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID24716847", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC5" ], "favors_models": [ "M4" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "mixed", "what_it_shows": "A randomized transdermal testosterone trial improved its verbal-learning task but not other cognitive domains or general wellbeing.", "what_it_does_not_show": "One modest task-specific signal is neither prevention of dementia nor evidence of generalized energy and muscle benefits.", "confounders_present": [ "One modest task-specific signal is neither prevention of dementia nor evidence of generalized energy and muscle benefits." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 32, "pmid": "20667535", "title": "A randomized trial of the effect of testosterone and estrogen on verbal fluency, verbal memory, and spatial ability in healthy postmenopausal women.", "citation": "Kocoska-Maras L, Zethraeus N, Rådestad AF et al. A randomized trial of the effect of testosterone and estrogen on verbal fluency, verbal memory, and spatial ability in healthy postmenopausal women. Fertility and sterility. 2011.", "doi": "10.1016/j.fertnstert.2010.05.062", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/20667535/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/20667535/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "Testosterone-estrogen-cognition-200women", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC5" ], "favors_models": [ "M4" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "null", "what_it_shows": "A randomized estrogen/testosterone/placebo trial found no substantial four-week differences in verbal or spatial cognition.", "what_it_does_not_show": "Short duration and oral regimens do not settle longer transdermal exposure or dementia endpoints.", "confounders_present": [ "Short duration and oral regimens do not settle longer transdermal exposure or dementia endpoints." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 33, "pmid": "22967437", "title": "Cognitive function in association with sex hormones in postmenopausal women.", "citation": "Kocoska-Maras L, Rådestad AF, Carlström K et al. Cognitive function in association with sex hormones in postmenopausal women. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2013.", "doi": "10.3109/09513590.2012.705385", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/22967437/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/22967437/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "Testosterone-estrogen-cognition-200women", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC5" ], "favors_models": [ "M4" ], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "Secondary hormone-level analyses found domain-specific associations in the same randomized cohort.", "what_it_does_not_show": "Correlations among post-treatment hormones and scores do not manipulate a mediator or add an independent efficacy trial.", "confounders_present": [ "Correlations among post-treatment hormones and scores do not manipulate a mediator or add an independent efficacy trial." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 34, "pmid": "25430996", "title": "Effects of testosterone administration on cognitive function in hysterectomized women with low testosterone levels: a dose-response randomized trial.", "citation": "Huang G, Wharton W, Travison TG et al. Effects of testosterone administration on cognitive function in hysterectomized women with low testosterone levels: a dose-response randomized trial. Journal of endocrinological investigation. 2015.", "doi": "10.1007/s40618-014-0213-3", "pmcid": "PMC4716804", "url": "https://pubmed.ncbi.nlm.nih.gov/25430996/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/25430996/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "Testosterone-dose-response-NCT00494208", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph1, 1:Methods:paragraph2, 1:Methods:paragraph4, 2:Results:paragraph0, 2:Results:paragraph3. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC5" ], "favors_models": [ "M4" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "null", "what_it_shows": "A testosterone dose-ranging trial found no benefit across tested cognitive domains over twenty-four weeks despite verified exposure.", "what_it_does_not_show": "Only participants with complete cognitive data were analyzed; small dose groups limit precision and share a parent with muscle outcomes.", "confounders_present": [ "Only participants with complete cognitive data were analyzed; small dose groups limit precision and share a parent with muscle outcomes." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 35, "pmid": "16837882", "title": "Testosterone aromatization and cognition in women: a randomized, placebo-controlled trial.", "citation": "Shah S, Bell RJ, Savage G et al. Testosterone aromatization and cognition in women: a randomized, placebo-controlled trial. Menopause (New York, N.Y.). 2006.", "doi": "10.1097/01.gme.0000227333.50867.4e", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/16837882/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/16837882/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID16837882", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC5" ], "favors_models": [ "M4" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "null", "what_it_shows": "Aromatase inhibition did not alter cognition in estrogen-treated women receiving testosterone in both randomized arms.", "what_it_does_not_show": "Without a testosterone-free randomized arm, within-group improvement cannot establish testosterone efficacy.", "confounders_present": [ "Without a testosterone-free randomized arm, within-group improvement cannot establish testosterone efficacy." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 36, "pmid": "11872200", "title": "Estrogen raises the sweating threshold in postmenopausal women with hot flashes.", "citation": "Freedman RR, Blacker CM. Estrogen raises the sweating threshold in postmenopausal women with hot flashes. Fertility and sterility. 2002.", "doi": "10.1016/s0015-0282(01)03009-6", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/11872200/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/11872200/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID11872200", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [ "M1", "M4" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Randomized estradiol raised sweating threshold and reduced objectively recorded laboratory hot flashes compared with placebo.", "what_it_does_not_show": "Small physiological trial narrows diary expectation but does not prove the complete estrogen–KNDy mediator sequence or all individual responses.", "confounders_present": [ "Small physiological trial narrows diary expectation but does not prove the complete estrogen–KNDy mediator sequence or all individual responses." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 37, "pmid": "10411797", "title": "Reduced thermoregulatory null zone in postmenopausal women with hot flashes.", "citation": "Freedman RR, Krell W. Reduced thermoregulatory null zone in postmenopausal women with hot flashes. American journal of obstetrics and gynecology. 1999.", "doi": "10.1016/s0002-9378(99)70437-0", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/10411797/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/10411797/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID10411797", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [ "M1", "M2" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Controlled heating/cooling and exercise showed narrowed thermoregulatory zones and heat-triggered flushing in symptomatic women.", "what_it_does_not_show": "Exposure groups were not randomized for estrogen deficiency; this is thermoregulatory discrimination, not proof estrogen alone causes all symptoms.", "confounders_present": [ "Exposure groups were not randomized for estrogen deficiency; this is thermoregulatory discrimination, not proof estrogen alone causes all symptoms." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 38, "pmid": "15772562", "title": "Effects of symptomatic status and the menstrual cycle on hot flash-related thermoregulatory parameters.", "citation": "Freedman RR, Subramanian M. Effects of symptomatic status and the menstrual cycle on hot flash-related thermoregulatory parameters. Menopause (New York, N.Y.). 2005.", "doi": "10.1097/00042192-200512020-00009", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/15772562/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/15772562/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID15772562", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [ "M1", "M2" ], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "Symptomatic women had lower sweating thresholds and greater sweat rates than asymptomatic/eumenorrheic groups despite similar explanatory hormone levels.", "what_it_does_not_show": "Small nonrandomized groups support a thermoregulatory phenotype but not an exclusive sex-steroid cause.", "confounders_present": [ "Small nonrandomized groups support a thermoregulatory phenotype but not an exclusive sex-steroid cause." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 39, "pmid": "23481119", "title": "Adverse effects of induced hot flashes on objectively recorded and subjectively reported sleep: results of a gonadotropin-releasing hormone agonist experimental protocol.", "citation": "Joffe H, White DP, Crawford SL et al. Adverse effects of induced hot flashes on objectively recorded and subjectively reported sleep: results of a gonadotropin-releasing hormone agonist experimental protocol. Menopause (New York, N.Y.). 2013.", "doi": "10.1097/GME.0b013e31828292d1", "pmcid": "PMC3687015", "url": "https://pubmed.ncbi.nlm.nih.gov/23481119/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/23481119/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID23481119", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [ "M1", "M2" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "GnRH agonist-induced ovarian suppression produced new hot flashes, with objective and subjective sleep effects differing by measurement.", "what_it_does_not_show": "Uncontrolled induction and post-outcome symptom grouping do not isolate estrogen from all GnRH effects or prove every sleep problem is vasomotor.", "confounders_present": [ "Uncontrolled induction and post-outcome symptom grouping do not isolate estrogen from all GnRH effects or prove every sleep problem is vasomotor." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [ "Joffe GnRHa induction program", "similar endocrine suppression and physiological measurement platform; participant overlap not established" ] }, { "n": 40, "pmid": "24293774", "title": "A gonadotropin-releasing hormone agonist model demonstrates that nocturnal hot flashes interrupt objective sleep.", "citation": "Joffe H, Crawford S, Economou N et al. A gonadotropin-releasing hormone agonist model demonstrates that nocturnal hot flashes interrupt objective sleep. Sleep. 2013.", "doi": "10.5665/sleep.3244", "pmcid": "PMC3825449", "url": "https://pubmed.ncbi.nlm.nih.gov/24293774/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/24293774/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID24293774", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [ "M1", "M2" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "A GnRH-agonist model associated induced nighttime hot flashes with greater polysomnographic sleep fragmentation.", "what_it_does_not_show": "Within-experiment symptom correlations are not an independently randomized mediator; related clinical protocol may share participants and instruments.", "confounders_present": [ "Within-experiment symptom correlations are not an independently randomized mediator; related clinical protocol may share participants and instruments." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [ "Joffe GnRHa induction program", "similar endocrine suppression and physiological measurement platform; participant overlap not established" ] }, { "n": 41, "pmid": "23545794", "title": "Effects of pharmacologically induced hypogonadism on mood and behavior in healthy young women.", "citation": "Ben Dor R, Harsh VL, Fortinsky P et al. Effects of pharmacologically induced hypogonadism on mood and behavior in healthy young women. The American journal of psychiatry. 2013.", "doi": "10.1176/appi.ajp.2012.12010117", "pmcid": "PMC3952563", "url": "https://pubmed.ncbi.nlm.nih.gov/23545794/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/23545794/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID23545794", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [ "M1", "M2" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "Induced hypogonadism increased nighttime hot flashes and disturbed sleep but rarely clinically significant depressive symptoms in screened healthy women.", "what_it_does_not_show": "No placebo induction group; psychiatric-history exclusions prevent transfer to women with prior mood disorders.", "confounders_present": [ "No placebo induction group; psychiatric-history exclusions prevent transfer to women with prior mood disorders." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 42, "pmid": "25683060", "title": "Neurokinin B administration induces hot flushes in women.", "citation": "Jayasena CN, Comninos AN, Stefanopoulou E et al. Neurokinin B administration induces hot flushes in women. Scientific reports. 2015.", "doi": "10.1038/srep08466", "pmcid": "PMC4329553", "url": "https://pubmed.ncbi.nlm.nih.gov/25683060/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/25683060/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID25683060", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 0:Methods:paragraph2, 0:Methods:paragraph5, 0:Methods:paragraph6, 1:Results:paragraph3, 1:Results:paragraph4, 1:Results:paragraph7. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [ "M1", "M2" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Blinded neurokinin-B infusion caused flushing with objective heat-dissipation changes in healthy women without measured estradiol change.", "what_it_does_not_show": "Exogenous challenge is a pathway sufficiency test, not proof hormone withdrawal or endogenous NKB is necessary in every menopausal flush.", "confounders_present": [ "Exogenous challenge is a pathway sufficiency test, not proof hormone withdrawal or endogenous NKB is necessary in every menopausal flush." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 43, "pmid": "28385352", "title": "Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial.", "citation": "Prague JK, Roberts RE, Comninos AN et al. Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2017.", "doi": "10.1016/S0140-6736(17)30823-1", "pmcid": "PMC5439024", "url": "https://pubmed.ncbi.nlm.nih.gov/28385352/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/28385352/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID28385352", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [ "M1", "M2" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "A blinded NK3-antagonist crossover trial reduced menopausal hot-flush frequency compared with placebo.", "what_it_does_not_show": "Small sample, incomplete completion and liver-enzyme elevations limit broad efficacy and safety predictions; it tests a nonhormonal pathway.", "confounders_present": [ "Small sample, incomplete completion and liver-enzyme elevations limit broad efficacy and safety predictions; it tests a nonhormonal pathway." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 44, "pmid": "25988798", "title": "κ Agonists as a novel therapy for menopausal hot flashes.", "citation": "Oakley AE, Steiner RA, Chavkin C et al. κ Agonists as a novel therapy for menopausal hot flashes. Menopause (New York, N.Y.). 2015.", "doi": "10.1097/GME.0000000000000476", "pmcid": "PMC4651855", "url": "https://pubmed.ncbi.nlm.nih.gov/25988798/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/25988798/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID25988798", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [ "M1", "M2" ], "evidence_class": "Weak", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "An acute kappa-agonist pilot reduced hot-flash frequency relative to placebo in a small crossover sample.", "what_it_does_not_show": "Very small analyzed group, acute exposure and opioid subjective effects limit blinding and long-term causal interpretation.", "confounders_present": [ "Very small analyzed group, acute exposure and opioid subjective effects limit blinding and long-term causal interpretation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 45, "pmid": "36924778", "title": "Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.", "citation": "Lederman S, Ottery FD, Cano A et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet (London, England). 2023.", "doi": "10.1016/S0140-6736(23)00085-5", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/36924778/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/36924778/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID36924778", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [ "M1", "M2" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "SKYLIGHT1 found reduced vasomotor frequency/severity with fezolinetant at tested doses during its placebo-controlled interval.", "what_it_does_not_show": "Nonhormonal efficacy does not prove systemic MHT prevention or necessity; later extension lacks ongoing placebo comparison.", "confounders_present": [ "Nonhormonal efficacy does not prove systemic MHT prevention or necessity; later extension lacks ongoing placebo comparison." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 46, "pmid": "40920404", "title": "Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: A Phase 3 Randomized Clinical Trial.", "citation": "Panay N, Joffe H, Maki PM et al. Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: A Phase 3 Randomized Clinical Trial. JAMA internal medicine. 2025.", "doi": "10.1001/jamainternmed.2025.4421", "pmcid": "PMC12418220", "url": "https://pubmed.ncbi.nlm.nih.gov/40920404/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40920404/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID40920404", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph1, 1:Methods:paragraph4, 1:Methods:paragraph8, 2:Results:paragraph10, 2:Results:paragraph11, 2:Results:paragraph13. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [ "M1", "M2" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "OASIS3 elinzanetant reduced its prespecified twelve-week vasomotor-frequency endpoint; later symptoms favored treatment descriptively.", "what_it_does_not_show": "Longer secondary/exploratory endpoints were not powered confirmatory tests, and treatment-related adverse events were more frequent.", "confounders_present": [ "Longer secondary/exploratory endpoints were not powered confirmatory tests, and treatment-related adverse events were more frequent." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 47, "pmid": "36734148", "title": "Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT.", "citation": "Johnson KA, Martin N, Nappi RE et al. Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT. The Journal of clinical endocrinology and metabolism. 2023.", "doi": "10.1210/clinem/dgad058", "pmcid": "PMC10348473", "url": "https://pubmed.ncbi.nlm.nih.gov/36734148/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/36734148/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID36734148", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [ "M1", "M2" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "SKYLIGHT2 reproduced fezolinetant vasomotor-frequency and severity benefits during placebo-controlled treatment.", "what_it_does_not_show": "Same pharmacological class and diary platform are replication rather than a new independent causal modality.", "confounders_present": [ "Same pharmacological class and diary platform are replication rather than a new independent causal modality." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 48, "pmid": "36897180", "title": "Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial.", "citation": "Neal-Perry G, Cano A, Lederman S et al. Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial. Obstetrics and gynecology. 2023.", "doi": "10.1097/AOG.0000000000005114", "pmcid": "PMC10026946", "url": "https://pubmed.ncbi.nlm.nih.gov/36897180/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/36897180/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID36897180", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [ "M1", "M2" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "SKYLIGHT4 characterized one-year endometrial, liver and bone safety under randomized fezolinetant exposure.", "what_it_does_not_show": "Safety-focused endpoints are not evidence of estrogen replacement efficacy or an assurance against rare postmarketing liver injury.", "confounders_present": [ "Safety-focused endpoints are not evidence of estrogen replacement efficacy or an assurance against rare postmarketing liver injury." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 49, "pmid": "39557487", "title": "Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial.", "citation": "Schaudig K, Wang X, Bouchard C et al. Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial. BMJ (Clinical research ed.). 2024.", "doi": "10.1136/bmj-2024-079525", "pmcid": "PMC11571049", "url": "https://pubmed.ncbi.nlm.nih.gov/39557487/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39557487/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "ErratumIn: PMID39603693" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID39557487", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [ "M1", "M2" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "DAYLIGHT reduced hot-flush frequency/severity and sleep disturbance in women considered unsuitable for hormone therapy.", "what_it_does_not_show": "Most participants were averse or caution categories rather than contraindicated; attached correction and finite follow-up constrain safety generalization.", "confounders_present": [ "Most participants were averse or caution categories rather than contraindicated; attached correction and finite follow-up constrain safety generalization." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 50, "pmid": "38818888", "title": "Efficacy and safety of fezolinetant for moderate to severe vasomotor symptoms associated with menopause among women in East Asia: a phase 3 randomized study (MOONLIGHT I).", "citation": "Ruan X, Bai W, Ren M et al. Efficacy and safety of fezolinetant for moderate to severe vasomotor symptoms associated with menopause among women in East Asia: a phase 3 randomized study (MOONLIGHT I). The Journal of international medical research. 2024.", "doi": "10.1177/03000605241247684", "pmcid": "PMC11143828", "url": "https://pubmed.ncbi.nlm.nih.gov/38818888/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38818888/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID38818888", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [ "M1", "M2" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "null", "what_it_shows": "MOONLIGHTI found no significant vasomotor-frequency or severity advantage for the tested fezolinetant dose in East Asian women.", "what_it_does_not_show": "A regimen/context null restricts generalization but does not erase positive trials at other doses or populations.", "confounders_present": [ "A regimen/context null restricts generalization but does not erase positive trials at other doses or populations." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 51, "pmid": "32102086", "title": "A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause.", "citation": "Fraser GL, Lederman S, Waldbaum A et al. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause. Menopause (New York, N.Y.). 2020.", "doi": "10.1097/GME.0000000000001510", "pmcid": "PMC7147405", "url": "https://pubmed.ncbi.nlm.nih.gov/32102086/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32102086/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID32102086", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [ "M1", "M2" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "VESTA dose-ranging NK3 blockade improved vasomotor frequency at tested doses and severity at some regimens.", "what_it_does_not_show": "Multiple dose arms share one study; diary responses and variable severity results constrain precise prediction.", "confounders_present": [ "Multiple dose arms share one study; diary responses and variable severity results constrain precise prediction." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 52, "pmid": "31415087", "title": "Treatment of Menopausal Vasomotor Symptoms With Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a Trial.", "citation": "Depypere H, Timmerman D, Donders G et al. Treatment of Menopausal Vasomotor Symptoms With Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a Trial. The Journal of clinical endocrinology and metabolism. 2019.", "doi": "10.1210/jc.2019-00677", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/31415087/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/31415087/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID31415087", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [ "M1", "M2" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "A fezolinetant phase2a placebo-controlled trial reduced vasomotor score and reported frequency.", "what_it_does_not_show": "Small selected cohort and one regimen do not establish universal response or lifetime safety.", "confounders_present": [ "Small selected cohort and one regimen do not establish universal response or lifetime safety." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 53, "pmid": "12117397", "title": "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.", "citation": "Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002.", "doi": "10.1001/jama.288.3.321", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/12117397/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/12117397/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "WHI-EplusP", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M4" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "contradicts", "what_it_shows": "WHI combined oral CEE/MPA had an unfavorable overall prevention risk–benefit balance despite fracture benefits.", "what_it_does_not_show": "Regimen and enrollment ages matter; results do not refute symptom efficacy or establish the risk of every modern formulation.", "confounders_present": [ "Regimen and enrollment ages matter; results do not refute symptom efficacy or establish the risk of every modern formulation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 54, "pmid": "15082697", "title": "Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.", "citation": "Anderson GL, Limacher M, Assaf AR et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004.", "doi": "10.1001/jama.291.14.1701", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/15082697/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/15082697/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "WHI-CEEalone", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M4" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "contradicts", "what_it_shows": "WHI CEE-alone increased stroke risk, reduced hip fractures and did not demonstrate coronary prevention or overall net benefit.", "what_it_does_not_show": "Hysterectomy cohort and oral CEE cannot be treated as the same population/regimen as combined therapy.", "confounders_present": [ "Hysterectomy cohort and oral CEE cannot be treated as the same population/regimen as combined therapy." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 55, "pmid": "12771112", "title": "Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.", "citation": "Shumaker SA, Legault C, Rapp SR et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003.", "doi": "10.1001/jama.289.20.2651", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/12771112/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/12771112/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "WHI-EplusP", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M4" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "contradicts", "what_it_shows": "WHIMS combined therapy increased probable dementia in women enrolled aged at least sixty-five and did not prevent mild cognitive impairment.", "what_it_does_not_show": "Age and CEE/MPA regimen limit extrapolation to early-menopause modern therapy; dementia is distinct from acute cognitive tests.", "confounders_present": [ "Age and CEE/MPA regimen limit extrapolation to early-menopause modern therapy; dementia is distinct from acute cognitive tests." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 56, "pmid": "15213206", "title": "Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.", "citation": "Shumaker SA, Legault C, Kuller L et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004.", "doi": "10.1001/jama.291.24.2947", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/15213206/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/15213206/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "WHI-CEEalone", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M4" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "contradicts", "what_it_shows": "WHIMS estrogen-alone did not reduce dementia or mild cognitive impairment, and pooled trials showed increased risk.", "what_it_does_not_show": "The estrogen-alone dementia estimate was imprecise; pooled WHI reports are not extra independent studies.", "confounders_present": [ "The estrogen-alone dementia estimate was imprecise; pooled WHI reports are not extra independent studies." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 57, "pmid": "27028912", "title": "Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol.", "citation": "Hodis HN, Mack WJ, Henderson VW et al. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. The New England journal of medicine. 2016.", "doi": "10.1056/NEJMoa1505241", "pmcid": "PMC4921205", "url": "https://pubmed.ncbi.nlm.nih.gov/27028912/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/27028912/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "ELITE-NCT00114517", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 0:METHODS:paragraph0, 0:METHODS:paragraph2, 0:METHODS:paragraph5, 0:METHODS:paragraph6, 1:RESULTS:paragraph2, 1:RESULTS:paragraph3, 1:RESULTS:paragraph6. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M4" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "mixed", "what_it_shows": "ELITE slowed carotid intima-media progression only with early estradiol initiation, without corresponding coronary CT differences.", "what_it_does_not_show": "Surrogate progression and sparse clinical events do not establish net cardiovascular or dementia prevention.", "confounders_present": [ "Surrogate progression and sparse clinical events do not establish net cardiovascular or dementia prevention." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 58, "pmid": "27421538", "title": "Cognitive effects of estradiol after menopause: A randomized trial of the timing hypothesis.", "citation": "Henderson VW, St John JA, Hodis HN et al. Cognitive effects of estradiol after menopause: A randomized trial of the timing hypothesis. Neurology. 2016.", "doi": "10.1212/WNL.0000000000002980", "pmcid": "PMC4999165", "url": "https://pubmed.ncbi.nlm.nih.gov/27421538/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/27421538/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "ELITE-NCT00114517", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M4" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "null", "what_it_shows": "ELITE cognitive outcomes showed no verbal-memory, executive or global-cognition benefit with early or later estradiol initiation.", "what_it_does_not_show": "Several years of cognitive tests cannot exclude later dementia prevention; same parent as the vascular report.", "confounders_present": [ "Several years of cognitive tests cannot exclude later dementia prevention; same parent as the vascular report." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 59, "pmid": "26035291", "title": "Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS-Cognitive and Affective Study.", "citation": "Gleason CE, Dowling NM, Wharton W et al. Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS-Cognitive and Affective Study. PLoS medicine. 2015.", "doi": "10.1371/journal.pmed.1001833", "pmcid": "PMC4452757", "url": "https://pubmed.ncbi.nlm.nih.gov/26035291/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/26035291/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "KEEPS-NCT00154180", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph4, 1:Methods:paragraph6, 1:Methods:paragraph8, 1:Methods:paragraph22, 2:Results:paragraph1, 2:Results:paragraph4, 2:Results:paragraph12, 2:Results:paragraph14. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [ "M1", "M4" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "mixed", "what_it_shows": "KEEPS showed vasomotor relief but no cognitive benefit; oral CEE improved selected mood scores while transdermal estradiol did not.", "what_it_does_not_show": "Cognitively healthy low-risk recent-menopause users, attrition and finite horizon constrain disease-prevention inference.", "confounders_present": [ "Cognitively healthy low-risk recent-menopause users, attrition and finite horizon constrain disease-prevention inference." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 60, "pmid": "38595196", "title": "Use of menopausal hormone therapy beyond age 65 years and its effects on women's health outcomes by types, routes, and doses.", "citation": "Baik SH, Baye F, McDonald CJ. Use of menopausal hormone therapy beyond age 65 years and its effects on women's health outcomes by types, routes, and doses. Menopause (New York, N.Y.). 2024.", "doi": "10.1097/GME.0000000000002335", "pmcid": "PMC11465799", "url": "https://pubmed.ncbi.nlm.nih.gov/38595196/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38595196/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID38595196", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M4" ], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Large Medicare analyses associate certain hormone formulations/routes with lower mortality and selected disease risks after age sixty-five.", "what_it_does_not_show": "Healthy-user, prescribing, continuation and confounding-by-indication effects remain; sample size does not randomize exposure.", "confounders_present": [ "Healthy-user, prescribing, continuation and confounding-by-indication effects remain; sample size does not randomize exposure." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 61, "pmid": "24861828", "title": "Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial.", "citation": "Joffe H, Guthrie KA, LaCroix AZ et al. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. JAMA internal medicine. 2014.", "doi": "10.1001/jamainternmed.2014.1891", "pmcid": "PMC4179877", "url": "https://pubmed.ncbi.nlm.nih.gov/24861828/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/24861828/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID24861828", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:METHODS:paragraph0, 1:METHODS:paragraph3, 1:METHODS:paragraph6, 1:METHODS:paragraph8, 2:RESULTS:paragraph1, 2:RESULTS:paragraph2, 2:RESULTS:paragraph3. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2" ], "favors_models": [ "M1", "M4" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "MsFLASH randomized estradiol and venlafaxine both reduced bothersome vasomotor frequency more than placebo.", "what_it_does_not_show": "The between-active-treatment contrast was imprecise; short follow-up cannot establish general hormone superiority or disease prevention.", "confounders_present": [ "The between-active-treatment contrast was imprecise; short follow-up cannot establish general hormone superiority or disease prevention." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 62, "pmid": "29889748", "title": "A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial.", "citation": "Lobo RA, Archer DF, Kagan R et al. A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial. Obstetrics and gynecology. 2018.", "doi": "10.1097/AOG.0000000000002645", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/29889748/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/29889748/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "ErratumIn: PMID30134411" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "REPLENISH-NCT01942668", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2" ], "favors_models": [ "M1", "M4" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "REPLENISH tested oral estradiol/progesterone versus placebo and found vasomotor-frequency/severity benefit at several doses.", "what_it_does_not_show": "Dose-specific coprimary results and finite endometrial analysis population do not prove zero lifetime risk; attached correction details require separate checking.", "confounders_present": [ "Dose-specific coprimary results and finite endometrial analysis population do not prove zero lifetime risk; attached correction details require separate checking." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 63, "pmid": "24281237", "title": "Testosterone dose-response relationships in hysterectomized women with or without oophorectomy: effects on sexual function, body composition, muscle performance and physical function in a randomized trial.", "citation": "Huang G, Basaria S, Travison TG et al. Testosterone dose-response relationships in hysterectomized women with or without oophorectomy: effects on sexual function, body composition, muscle performance and physical function in a randomized trial. Menopause (New York, N.Y.). 2014.", "doi": "10.1097/GME.0000000000000093", "pmcid": "PMC4701202", "url": "https://pubmed.ncbi.nlm.nih.gov/24281237/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/24281237/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "Testosterone-dose-response-NCT00494208", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:METHODS:paragraph0, 1:METHODS:paragraph1, 1:METHODS:paragraph3, 1:METHODS:paragraph6, 1:METHODS:paragraph7, 2:RESULTS:paragraph3, 2:RESULTS:paragraph6, 2:RESULTS:paragraph7, 3:DISCUSSION:paragraph1, 3:DISCUSSION:paragraph4. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC5" ], "favors_models": [ "M4" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "mixed", "what_it_shows": "Testosterone dose-ranging produced lean-mass and selected muscle-power gains mainly at supraphysiologic exposure, with several physical-function tests unchanged.", "what_it_does_not_show": "Small dose groups, secondary outcomes and late trial registration limit prediction; high-dose gains cannot establish physiological replacement benefit.", "confounders_present": [ "Small dose groups, secondary outcomes and late trial registration limit prediction; high-dose gains cannot establish physiological replacement benefit." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 64, "pmid": "24712568", "title": "Testosterone dose-response relationships with cardiovascular risk markers in androgen-deficient women: a randomized, placebo-controlled trial.", "citation": "Huang G, Tang E, Aakil A et al. Testosterone dose-response relationships with cardiovascular risk markers in androgen-deficient women: a randomized, placebo-controlled trial. The Journal of clinical endocrinology and metabolism. 2014.", "doi": "10.1210/jc.2013-4160", "pmcid": "PMC4079305", "url": "https://pubmed.ncbi.nlm.nih.gov/24712568/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/24712568/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "Testosterone-dose-response-NCT00494208", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC5" ], "favors_models": [ "M4" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "null", "what_it_shows": "The same testosterone dose-response parent trial found no major changes in measured cardiometabolic risk markers.", "what_it_does_not_show": "Marker stability over a short interval cannot exclude clinical cardiovascular harms or establish metabolic prevention.", "confounders_present": [ "Marker stability over a short interval cannot exclude clinical cardiovascular harms or establish metabolic prevention." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] } ], "verification_summary": { "load_bearing_claims_checked": 70, "verified": 70, "unverified": 0, "contradicted": 0, "note": "Verified attribution is distinct from mechanism truth or complete body access." }, "factual_issues_found": [], "cap_rules_applied": [], "cap_precedence_resolutions": [ { "collision": "Perturbation in a defined setting versus broader inference", "subclaim_scope_cap_binds_on": "Systemic menopausal hormone therapy causes a reduction in bothersome vasomotor symptoms in perimenopausal and postmenopausal women.", "subclaim_scope_threshold_binds_on": "The precise experimentally tested subclaim scope", "resolution": "Under the prospectively declared clinical adaptation, hormone randomization crosses Δ for symptom outcomes in the population and horizon tested. Human-only clinical efficacy is not extrapolated from model organisms and is not a claim of slowed aging. Association, hormone-level changes and CIMT alone retain their respective Β/Γ inference ceilings. Null randomized prevention and cognitive trials do not earn positive crossings. The convergent symptom set is not re-capped on its observational withdrawal component, and same-parent reports are grouped.", "note": "Convergent lines are assessed as a set; one weak leg is not re-capped over the assembled case." } ], "boundary_check_BGD": [ { "subclaim_id": "SC1", "field_valid_perturbation_quote": "\n- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension\n- Must separate developmental effects from true aging effects\n- Biomarker change alone does NOT satisfy this threshold", "qualifying_evidence_present": "yes", "qualifying_evidence_citation": "PMID11872200, PMID23481119, PMID23545794, PMID25683060, PMID28385352", "gamma_hard_rules_triggered": [ "Suppression studies without randomized placebo have residual nonspecific effects; exogenous NKB is a controlled sufficiency challenge, not complete endogenous necessity." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "yes", "perturbation_result_note": "Hormone suppression and replacement, a predicted thermoregulatory response under randomized estradiol and mechanistically distinct NKB challenge/blockade support a causal endocrine–thermoregulatory contribution. Deficiency alone does not predict all symptoms; objective pathway tests and symptomatic/asymptomatic comparisons preserve this boundary. Ζ is contribution, not sole-cause necessity.", "ceiling_from_boundary_check": "Δ or higher" }, { "subclaim_id": "SC2", "field_valid_perturbation_quote": "\n- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension\n- Must separate developmental effects from true aging effects\n- Biomarker change alone does NOT satisfy this threshold", "qualifying_evidence_present": "yes", "qualifying_evidence_citation": "PMID10993030, PMID16735941, PMID34402360, PMID9840563, PMID3928674, PMID11872200, PMID24861828, PMID29889748", "gamma_hard_rules_triggered": [ "Objective physiological and blinded clinical endpoint evidence is present; biomarkers alone do not carry the grade. Blinding procedures were examined, but no complete allocation-guess audit is claimed." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "yes", "perturbation_result_note": "Repeated blinded hormone trials show symptom relief beyond placebo in baseline symptomatic women, including oral and transdermal regimens. MsFLASH provides an active nonhormonal comparison; objective sweating-threshold/flush experiments reduce a reporting-only explanation, and withdrawal observations agree with reversible control. Ζ reflects complementary failure structures; replication/report counts alone do not provide independence. Η would require stronger mediator isolation and prospective cross-context control of major exceptions.", "ceiling_from_boundary_check": "Δ or higher" }, { "subclaim_id": "SC3", "field_valid_perturbation_quote": "\n- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension\n- Must separate developmental effects from true aging effects\n- Biomarker change alone does NOT satisfy this threshold", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "", "gamma_hard_rules_triggered": [ "Biomarker-only improvement without organismal benefit restricts the supportive surrogate route; clinical nulls/harms do not become positive causal evidence." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "Net cardiovascular or neurodegenerative prevention does not inherit symptom efficacy. WHI/WHIMS and WISDOM supply direct regimen/age-specific clinical contradictions, while early ELITE CIMT and Medicare associations leave a narrower preventive possibility open. Positive surrogate/observational support is insufficient for hard prevention; the functional contradiction downgrades that supportive Γ-level route to Β. It is not a blanket claim all formulations or early symptomatic use are harmful.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC4", "field_valid_perturbation_quote": "\n- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension\n- Must separate developmental effects from true aging effects\n- Biomarker change alone does NOT satisfy this threshold", "qualifying_evidence_present": "yes", "qualifying_evidence_citation": "PMID20166859, PMID18987368, PMID15863529, PMID16014407, PMID16932240", "gamma_hard_rules_triggered": [ "Open-label extensions remain a Γ-limited safety-support class; the randomized HSDD endpoint evidence supplies the scoped crossing." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "yes", "perturbation_result_note": "Testosterone patch trials establish a modest causal sexual-function benefit in baseline diagnosed postmenopausal HSDD, with limits across dose, concurrent estrogen and endpoints. These replicated, closely related intervention platforms do not supply a separate orthogonal causal mechanism or all-women indication; Ε preserves the mapped clinical context and finite safety horizon.", "ceiling_from_boundary_check": "Δ or higher" }, { "subclaim_id": "SC5", "field_valid_perturbation_quote": "\n- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension\n- Must separate developmental effects from true aging effects\n- Biomarker change alone does NOT satisfy this threshold", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "", "gamma_hard_rules_triggered": [ "Open-label clinic data and correlated hormones do not cross Δ. Restricted positive controlled endpoints retain their small-sample/dose scope; null domains cannot be counted as positive." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "One verbal-learning outcome and high-exposure muscle/performance signals provide narrower clinical positives; these are retained with their doses and populations. They do not establish the bundled general cognition, energy and muscle proposition in women without HSDD. Multiple cognitive domains and wellbeing/fatigue outcomes are null. The full enhancement proposition retains partial support at Γ; this does not deny the separate HSDD clinical efficacy or the isolated task finding.", "ceiling_from_boundary_check": "Γ" } ], "thresholds_tested": [ { "subclaim_id": "SC1", "threshold": "Δ", "requirement_quoted": "Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.", "satisfied": "yes", "supporting_evidence": [ "[36] Randomized estradiol raised sweating threshold and reduced objectively recorded laboratory hot flashes compared with placebo.", "[39] GnRH agonist-induced ovarian suppression produced new hot flashes, with objective and subjective sleep effects differing by measurement.", "[41] Induced hypogonadism increased nighttime hot flashes and disturbed sleep but rarely clinically significant depressive symptoms in screened healthy women.", "[42] Blinded neurokinin-B infusion caused flushing with objective heat-dissipation changes in healthy women without measured estradiol change.", "[43] A blinded NK3-antagonist crossover trial reduced menopausal hot-flush frequency compared with placebo." ], "what_would_cross_it": "" }, { "subclaim_id": "SC1", "threshold": "Ε", "requirement_quoted": "Requires causal effect in constrained contexts, backgrounds, or species.", "satisfied": "yes", "supporting_evidence": [ "[36] Randomized estradiol raised sweating threshold and reduced objectively recorded laboratory hot flashes compared with placebo.", "[39] GnRH agonist-induced ovarian suppression produced new hot flashes, with objective and subjective sleep effects differing by measurement.", "[41] Induced hypogonadism increased nighttime hot flashes and disturbed sleep but rarely clinically significant depressive symptoms in screened healthy women.", "[42] Blinded neurokinin-B infusion caused flushing with objective heat-dissipation changes in healthy women without measured estradiol change.", "[43] A blinded NK3-antagonist crossover trial reduced menopausal hot-flush frequency compared with placebo." ], "what_would_cross_it": "" }, { "subclaim_id": "SC1", "threshold": "Ζ", "requirement_quoted": "Requires:\n- Reproducible intervention effects\n- Mechanistic narrowing\n- Evidence not reducible to general sickness, caloric reduction, or developmental artifacts", "satisfied": "yes", "supporting_evidence": [ "[36] Randomized estradiol raised sweating threshold and reduced objectively recorded laboratory hot flashes compared with placebo.", "[39] GnRH agonist-induced ovarian suppression produced new hot flashes, with objective and subjective sleep effects differing by measurement.", "[41] Induced hypogonadism increased nighttime hot flashes and disturbed sleep but rarely clinically significant depressive symptoms in screened healthy women.", "[42] Blinded neurokinin-B infusion caused flushing with objective heat-dissipation changes in healthy women without measured estradiol change.", "[43] A blinded NK3-antagonist crossover trial reduced menopausal hot-flush frequency compared with placebo." ], "what_would_cross_it": "" }, { "subclaim_id": "SC1", "threshold": "Η", "requirement_quoted": "Requires:\n- Robust cross-context intervention evidence\n- Mechanistic specificity\n- Strong alignment of lifespan/healthspan outcomes", "satisfied": "no", "supporting_evidence": [ "[36] Randomized estradiol raised sweating threshold and reduced objectively recorded laboratory hot flashes compared with placebo.", "[39] GnRH agonist-induced ovarian suppression produced new hot flashes, with objective and subjective sleep effects differing by measurement.", "[41] Induced hypogonadism increased nighttime hot flashes and disturbed sleep but rarely clinically significant depressive symptoms in screened healthy women.", "[42] Blinded neurokinin-B infusion caused flushing with objective heat-dissipation changes in healthy women without measured estradiol change.", "[43] A blinded NK3-antagonist crossover trial reduced menopausal hot-flush frequency compared with placebo." ], "what_would_cross_it": "A selective, reversible human endocrine/thermoregulatory mediation experiment must demonstrate how steroid withdrawal alters measured downstream circuitry and symptoms, with objective sensing, allocation-guess checks and symptomatic/asymptomatic baseline contrasts." }, { "subclaim_id": "SC2", "threshold": "Δ", "requirement_quoted": "Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.", "satisfied": "yes", "supporting_evidence": [ "[2] Randomized oral estradiol at two doses reduced hot-flush frequency compared with placebo over twelve weeks.", "[3] Two placebo-controlled oral estradiol acetate trials show dose-dependent timing and magnitude of symptom relief.", "[4] A Chinese randomized trial shows ultra-low estradiol/dydrogesterone reduces daily hot flushes more than placebo.", "[5] PEPI hormone regimens reduce vasomotor symptoms while anxiety, cognitive and affective checklist outcomes show no treatment difference.", "[6] Randomized transdermal estradiol produced exposure-dependent hot-flush suppression at tested doses.", "[36] Randomized estradiol raised sweating threshold and reduced objectively recorded laboratory hot flashes compared with placebo.", "[61] MsFLASH randomized estradiol and venlafaxine both reduced bothersome vasomotor frequency more than placebo.", "[62] REPLENISH tested oral estradiol/progesterone versus placebo and found vasomotor-frequency/severity benefit at several doses." ], "what_would_cross_it": "" }, { "subclaim_id": "SC2", "threshold": "Ε", "requirement_quoted": "Requires causal effect in constrained contexts, backgrounds, or species.", "satisfied": "yes", "supporting_evidence": [ "[2] Randomized oral estradiol at two doses reduced hot-flush frequency compared with placebo over twelve weeks.", "[3] Two placebo-controlled oral estradiol acetate trials show dose-dependent timing and magnitude of symptom relief.", "[4] A Chinese randomized trial shows ultra-low estradiol/dydrogesterone reduces daily hot flushes more than placebo.", "[5] PEPI hormone regimens reduce vasomotor symptoms while anxiety, cognitive and affective checklist outcomes show no treatment difference.", "[6] Randomized transdermal estradiol produced exposure-dependent hot-flush suppression at tested doses.", "[36] Randomized estradiol raised sweating threshold and reduced objectively recorded laboratory hot flashes compared with placebo.", "[61] MsFLASH randomized estradiol and venlafaxine both reduced bothersome vasomotor frequency more than placebo.", "[62] REPLENISH tested oral estradiol/progesterone versus placebo and found vasomotor-frequency/severity benefit at several doses." ], "what_would_cross_it": "" }, { "subclaim_id": "SC2", "threshold": "Ζ", "requirement_quoted": "Requires:\n- Reproducible intervention effects\n- Mechanistic narrowing\n- Evidence not reducible to general sickness, caloric reduction, or developmental artifacts", "satisfied": "yes", "supporting_evidence": [ "[2] Randomized oral estradiol at two doses reduced hot-flush frequency compared with placebo over twelve weeks.", "[3] Two placebo-controlled oral estradiol acetate trials show dose-dependent timing and magnitude of symptom relief.", "[4] A Chinese randomized trial shows ultra-low estradiol/dydrogesterone reduces daily hot flushes more than placebo.", "[5] PEPI hormone regimens reduce vasomotor symptoms while anxiety, cognitive and affective checklist outcomes show no treatment difference.", "[6] Randomized transdermal estradiol produced exposure-dependent hot-flush suppression at tested doses.", "[36] Randomized estradiol raised sweating threshold and reduced objectively recorded laboratory hot flashes compared with placebo.", "[61] MsFLASH randomized estradiol and venlafaxine both reduced bothersome vasomotor frequency more than placebo.", "[62] REPLENISH tested oral estradiol/progesterone versus placebo and found vasomotor-frequency/severity benefit at several doses." ], "what_would_cross_it": "" }, { "subclaim_id": "SC2", "threshold": "Η", "requirement_quoted": "Requires:\n- Robust cross-context intervention evidence\n- Mechanistic specificity\n- Strong alignment of lifespan/healthspan outcomes", "satisfied": "no", "supporting_evidence": [ "[2] Randomized oral estradiol at two doses reduced hot-flush frequency compared with placebo over twelve weeks.", "[3] Two placebo-controlled oral estradiol acetate trials show dose-dependent timing and magnitude of symptom relief.", "[4] A Chinese randomized trial shows ultra-low estradiol/dydrogesterone reduces daily hot flushes more than placebo.", "[5] PEPI hormone regimens reduce vasomotor symptoms while anxiety, cognitive and affective checklist outcomes show no treatment difference.", "[6] Randomized transdermal estradiol produced exposure-dependent hot-flush suppression at tested doses.", "[36] Randomized estradiol raised sweating threshold and reduced objectively recorded laboratory hot flashes compared with placebo.", "[61] MsFLASH randomized estradiol and venlafaxine both reduced bothersome vasomotor frequency more than placebo.", "[62] REPLENISH tested oral estradiol/progesterone versus placebo and found vasomotor-frequency/severity benefit at several doses." ], "what_would_cross_it": "A prospectively powered cross-context comparison should combine objective and patient-important symptoms, verified exposure, independent instruments and allocation-guess assessment, isolate the hormone-mediated dependency and replicate major age/formulation exceptions. This would support Η; reliable prospective individual prediction is needed for Θ." }, { "subclaim_id": "SC3", "threshold": "Δ", "requirement_quoted": "Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.", "satisfied": "no", "supporting_evidence": [], "what_would_cross_it": "A randomized early-initiation contemporary-regimen trial must demonstrate net reduction in hard cardiovascular or incident dementia outcomes, with complete harm ascertainment; surrogate improvement and observational continuation are insufficient." }, { "subclaim_id": "SC4", "threshold": "Δ", "requirement_quoted": "Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.", "satisfied": "yes", "supporting_evidence": [ "[18] ADORE found improved satisfying sexual events, desire and distress with a testosterone patch in naturally menopausal HSDD women.", "[19] APHRODITE found modest sexual-function benefit at the higher tested testosterone patch dose in postmenopausal HSDD women without estrogen.", "[20] A randomized patch trial improved sexual activity, desire and distress after surgical menopause with concomitant estrogen.", "[21] INTIMATE SM1 improved satisfying sexual activity and desire and reduced distress versus placebo after surgical menopause.", "[22] INTIMATE NM1 reported improved sexual events, desire and distress in naturally menopausal HSDD women taking estrogen." ], "what_would_cross_it": "" }, { "subclaim_id": "SC4", "threshold": "Ε", "requirement_quoted": "Requires causal effect in constrained contexts, backgrounds, or species.", "satisfied": "yes", "supporting_evidence": [ "[18] ADORE found improved satisfying sexual events, desire and distress with a testosterone patch in naturally menopausal HSDD women.", "[19] APHRODITE found modest sexual-function benefit at the higher tested testosterone patch dose in postmenopausal HSDD women without estrogen.", "[20] A randomized patch trial improved sexual activity, desire and distress after surgical menopause with concomitant estrogen.", "[21] INTIMATE SM1 improved satisfying sexual activity and desire and reduced distress versus placebo after surgical menopause.", "[22] INTIMATE NM1 reported improved sexual events, desire and distress in naturally menopausal HSDD women taking estrogen." ], "what_would_cross_it": "" }, { "subclaim_id": "SC4", "threshold": "Ζ", "requirement_quoted": "Requires:\n- Reproducible intervention effects\n- Mechanistic narrowing\n- Evidence not reducible to general sickness, caloric reduction, or developmental artifacts", "satisfied": "no", "supporting_evidence": [ "[18] ADORE found improved satisfying sexual events, desire and distress with a testosterone patch in naturally menopausal HSDD women.", "[19] APHRODITE found modest sexual-function benefit at the higher tested testosterone patch dose in postmenopausal HSDD women without estrogen.", "[20] A randomized patch trial improved sexual activity, desire and distress after surgical menopause with concomitant estrogen.", "[21] INTIMATE SM1 improved satisfying sexual activity and desire and reduced distress versus placebo after surgical menopause.", "[22] INTIMATE NM1 reported improved sexual events, desire and distress in naturally menopausal HSDD women taking estrogen." ], "what_would_cross_it": "Independent mechanistic manipulation or a distinct failure-resistant causal modality should support HSDD benefit beyond patch/sexual-diary replication, with prespecified physiological exposure and longer controlled safety follow-up." }, { "subclaim_id": "SC5", "threshold": "Δ", "requirement_quoted": "Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.", "satisfied": "no", "supporting_evidence": [], "what_would_cross_it": "Replicate patient-important cognition, fatigue/energy and muscle function at physiologic female exposure in baseline-defined women without HSDD; task-only, high-dose or lean-mass-only effects cannot establish the generalized package." } ], "generalization_check": { "generalization_tested": "yes", "context_boundary_mapped": "yes", "internal_negative_controls": [ "Asymptomatic postmenopausal women have different thermoregulatory responses despite low estrogen.", "MsFLASH placebo improved and venlafaxine was effective; MHT is not required for every episode of relief.", "KEEPS and ELITE cognitive outcomes did not inherit symptom or CIMT benefits.", "Testosterone lower doses and multiple nonspecific domains did not reproduce the HSDD benefit.", "MOONLIGHTI tested a regimen/population in which NK3 symptom efficacy failed to generalize." ], "note": "Symptom efficacy is replicated across selected systemic regimens and symptomatic cohorts, with meaningful baseline age/menopause-stage and dose boundaries. The review does not designate people as in scope because they responded. Rare serious harms, years of contemporary transdermal exposure, incident dementia and all-women testosterone claims remain separate. A trial selected for symptoms cannot establish prevention in asymptomatic users, and a prevention trial cannot be read as a universal ban on symptom treatment." }, "falsification_patterns_met": [ { "pattern": "Pathway manipulation changes biomarkers but not lifespan/healthspan", "evidence": "For SC3, the declared clinical prevention adaptation is triggered by ELITE surrogate support without hard prevention demonstration, together with WHI/WHIMS functional contradictions. The supportive surrogate route cannot rescue net prevention.", "downgrade_applied": true, "subclaim_id": "SC3", "downgrade_note": "Supportive Γ-level surrogate plausibility is downgraded one rung to Β for the registered hard prevention proposition; no extra repeated downgrade per null report." } ], "pitfalls_flagged": [ { "pitfall": "Mechanism conflation", "where": "Vasomotor benefit, dementia/cardiovascular prevention, HSDD treatment and generalized testosterone enhancement are separate subclaims." }, { "pitfall": "Confirmation by biomarker", "where": "CIMT, hormone levels and metabolic markers cannot stand in for net clinical prevention or subjective wellbeing." }, { "pitfall": "Replication confused with causal-line independence", "where": "Routes, sponsors, repeated WHI/REPLENISH reports and multiple doses do not create independent modalities." }, { "pitfall": "Scope fitted to the result", "where": "Symptoms, HSDD, age and regimen are defined before outcomes; retrospective responders are not a valid scope." }, { "pitfall": "Negative field-valid perturbation read as a crossed threshold", "where": "WHIMS, ELITE cognition, testosterone domain nulls and MOONLIGHTI remain discriminators rather than positive causal support." } ], "causal_tally_audit": { "tally_claimed_by_document": 15, "tally_after_audit": 15, "tally_unit": "Positive qualifying study units across scoped subclaims, not independent causal lines or full-claim necessity/sufficiency.", "screened_discriminating_contrasts": 42, "items_rejected": [ "Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines.", "Repeated parent-trial reports, pooled analyses, extensions and hormone correlations cannot add causal study units.", "Positive qualifying within-scope symptom/HSDD/task studies are not proof of general prevention or all-indication efficacy.", "The objective physiological prediction narrows a different measurement failure; other hormone trials replicate the same clinical allocation line." ] }, "steelman": { "case_one_rung_higher": "One rung above, Η: systemic hormone treatment repeatedly changes symptomatic trajectories, across oral and transdermal routes, with laboratory physiology and loss of benefit after cessation; the clinical claim is modest and well replicated. This is the strongest case for strong convergent intervention-sensitive evidence without demanding a lifespan outcome. The blocker is incomplete mediator isolation and quantified cross-context/blinding control, not the existence of WHI prevention harms in a separately scoped proposition.", "case_one_rung_lower": "One rung below, Ε: all positive clinical trials could be classified as one hormone modality with related subjective measurement, the physiological experiment is small, and withdrawal reports are selected/unblinded. This is a serious independence objection. The objective predicted thermoregulatory response measured outside diary reporting narrows a different systematic error; under the preregistered human clinical adaptation this plus controlled symptom allocation supports Ζ, with no claim that route/sponsor replication alone adds lines.", "which_rejected": "Retain Ζ for the clinical symptom claim, while exposing the clinical-rubric adaptation and the independence hinge. Reject Η pending mediation and prospective context checks. Reject Ε as the nominal because the separately instrumented, predicted physiological response complements randomized clinical symptom outcomes; retain Ε for the bounded testosterone indications/domains where analogous orthogonal convergence is absent. Prevention remains Β after its own contradictory clinical evidence.", "blocking_cap_threshold_or_missing_experiment": "Missing experiment: Run a prospectively registered, adequately powered symptomatic-menopause trial of a measured systemic estradiol regimen, placebo and a mechanistically distinct nonhormonal comparator, with identical contact, allocation-guess checks, objective thermal/skin-conductance sensing and daily patient-important symptoms. Embed baseline-defined age/stage and route strata and a blinded randomized-withdrawal phase; test the hypothesized mediator without conditioning on response. A separate long-horizon contemporary-regimen prevention trial is required for SC3." }, "final_score": { "hsef_level": "Ζ", "hsef_descriptor": "Multiple independent causal lines converge", "confidence": "High", "confidence_rationale": "64 primary reports with 8 selected partial-body examinations; evidence density, independent replication and heterogeneity of controls set the confidence; access depth and belief in correctness do not.", "rests_on_non_peer_reviewed_work": false, "rationale": "The registered primary-subclaim rule assigns Ζ with High confidence from SC2: systemic menopausal hormone therapy causes vasomotor symptom relief in baseline symptomatic women. Endocrine–thermoregulatory contribution is separately rated Ζ, prevention Β, testosterone for HSDD Ε, and broader testosterone enhancement Γ. Weakest-link would return Β for an unregistered conjunction of these different indications; primary-subclaim and scope-matched return Ζ. The symptom grade does not establish preventive or testosterone efficacy." }, "role_of_mechanism": { "classification": "reinforcing / stabilizing factor", "derivation_step_matched": 5, "derivation": "Menopausal ovarian transition lies upstream. Hormone replacement modulates and stabilizes thermoregulatory signaling and the relief trajectory; it is not necessary for all relief, since venlafaxine/NK3 blockade also work, and hormone deficiency alone does not initiate flushing in every woman. Directional steps1/2 do not fit an inert downstream marker, step3 does not meet universal initiation/necessity/rate-limiting requirements, and step4 cannot establish necessity. Step5 therefore supplies the limited stabilizing role, not a sole primary driver of all menopausal disease.", "tournament_used_as_tiebreaker": false, "note": "Derived from causal direction, not tournament rank." }, "extended_scoring_MSD": { "momentum": { "value": "Mechanistic only", "artifact": "The named artifact is the completed controlled neurokinin-pathway programme, OASIS3 (PMID40920404) and the earlier NK3 trials, plus comparative symptom studies; these test a nonhormonal pathway and specific treatment choices. No trial addressing this subclaim's boundary check — isolation of the hormone-mediated mediator with prospective cross-context control — was identified as underway, consistent with the Stability entry. No unverified named pending cardiovascular trial is asserted.", "justification": "The named artifact is the completed controlled neurokinin-pathway programme, OASIS3 (PMID40920404) and the earlier NK3 trials, plus comparative symptom studies; these test a nonhormonal pathway and specific treatment choices. No trial addressing this subclaim's boundary check — isolation of the hormone-mediated mediator with prospective cross-context control — was identified as underway, consistent with the Stability entry. No unverified named pending cardiovascular trial is asserted." }, "stability": { "value": "Stable", "trigger": "No verified pending result was identified that is likely to overturn the replicated short-horizon MHT symptom claim. A large prespecified objective/subjective trial with credible maintained blinding showing loss of active benefit would lower the grade; a mediator-isolation/replicated-context study could raise it, but these are proposed rather than falsely declared ongoing named triggers.", "justification": "No verified pending result was identified that is likely to overturn the replicated short-horizon MHT symptom claim. A large prespecified objective/subjective trial with credible maintained blinding showing loss of active benefit would lower the grade; a mediator-isolation/replicated-context study could raise it, but these are proposed rather than falsely declared ongoing named triggers." }, "divergence": { "implied_level": "Ζ", "implied_level_basis": "The MsFLASH original frames estrogen as a standard symptom treatment while its randomized data distinguish that efficacy from active-comparator superiority and from prevention. Within this exact symptomatic claim, convergent efficacy rather than universal necessity is the supported framing.", "assessed_level": "Ζ", "gap_in_rungs": 0, "value": "Aligned", "justification": "Scoped original clinical framing implies Ζ and assessed Ζ; 5 minus 5 = 0. This does not measure all social-media hormone narratives or imply aligned prevention claims." }, "calibration_note": "M/S/D never modify HSEF level or confidence." }, "change_record": { "applies": false, "prior_level": "none assigned", "prior_confidence": null, "prior_source": null, "derived_before_consulting_prior": true, "new_level": "Ζ", "direction": "newly assigned", "what_moved_it": "Fresh primary evidence appraisal; not blinded.", "divergence_from_other_reviewers": null }, "proposed_decisive_experiments": [ { "name": "Registered boundary experiment", "experiment": "Run a prospectively registered, adequately powered symptomatic-menopause trial of a measured systemic estradiol regimen, placebo and a mechanistically distinct nonhormonal comparator, with identical contact, allocation-guess checks, objective thermal/skin-conductance sensing and daily patient-important symptoms. Embed baseline-defined age/stage and route strata and a blinded randomized-withdrawal phase; test the hypothesized mediator without conditioning on response. A separate long-horizon contemporary-regimen prevention trial is required for SC3.", "readout": "Prespecified symptom frequency, severity and daily interference over 4–24 weeks, concordant independently sensed heat-dissipation episodes and reversible withdrawal response; prevention uses incident cardiovascular disease/dementia and complete benefit/harm composites.", "critical_control": "Intention-to-treat analysis, measured exposure, identical contact, credible placebo/comparator, prospective strata, missing-data sensitivity, independently blinded physiological assessors and no responder exclusions.", "supporting_result": "Persistent hormone-allocation effect beyond reporting/expectancy artifacts, concordant thermal physiology and reversible mediated response across registered strata would strengthen the clinical grade; hard net event reduction is separately needed for prevention.", "falsifying_result": "An adequately engaged trial losing symptom benefit against maintained blinding and independent objective measures would lower the clinical grade; improved markers without hard-event benefit would leave prevention unestablished." } ], "knowledge_gaps": [ { "name": "Gap 1", "statement": "The complete endocrine-to-thermoregulatory mediator sequence is not isolated by ordinary efficacy trials.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 2", "statement": "Allocation-guess assessment and objective symptom sensing are incompletely integrated in large hormone trials.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 3", "statement": "Long-term hard endpoints for contemporary transdermal estradiol/micronized progesterone begun near menopause need direct assessment rather than extrapolation from oral CEE/MPA or observational continuation.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 4", "statement": "Physiological-dose testosterone requires replicated patient-important nonspecific cognition, fatigue and muscle-function endpoints; supraphysiologic dose signals do not establish ordinary replacement benefit.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 5", "statement": "Rare breast, vascular and liver harms require formulation-specific long-term surveillance and cannot be excluded by small short trials.", "relevance": "Limits mechanism identification or scope." } ], "review_metadata": { "review_date": "2026-10-12", "reviewer": "Codex", "evidence_base_note": "64 primary reports; literature cutoff 2026-10-12; source examination UTC date 2026-10-13; bounded critical review, not exhaustive systematic review.", "literature_tools_available": true, "literature_tools_note": "Life Sciences Literature PubMed/Entrez, separately logged public original-body retrieval, and Consensus Pro browser searches. Provider output retained as observed browser text with citation-link mappings, or as previously exported connector documents where present. AI synthesis is not primary full-text verification. Consensus retrieved/included counts are not examined-primary counts. Scite monthly limit was reached earlier in this session; no new Scite query or incoming citation-context audit is claimed for these cases. Tool receipts record actual use. Supplementary discovery outputs do not earn primary-count credit. No independent blinded review.", "skill_version": "5.3", "validator_run": "PASS: exact archived HSEF v5.3 validator rerun after final sealing.", "validator_warnings_addressed": "No warnings.", "limits": "Bounded source-based critical review; no complete-paper/supplement audit, independent scientific peer review or blinded calibration. Revision cases retain original prose outside the three framework output blocks and have explicit correction logs." }, "is_calibration_entry": { "value": false, "entry_role": "not_calibration", "blind_graded": null, "completed_blinded_calibration": false, "expected_band_sealed_at": "", "target_sha256": "", "target_authorship": "not applicable", "target_author_saw_review": null, "future_run_status": "not prepared", "unblinded_reason": "These topic families were selected from an editorial traffic-priority list. Selection was visible; no blind calibration or predetermined clinical verdict was preregistered." }, "upper_ladder_check": { "final_level_below_zeta": false, "equivalents_considered": [ { "kind": "mendelian_randomization", "available": false, "why_not_sufficient": "The upper ladder is reachable for direct human clinical claims after the declared phenotype adaptation. Replicated symptomatic hormone intervention and an independently instrumented thermoregulatory prediction permit Ζ, with suppression/withdrawal complementary context. Η is held because the complete mediator dependency and major age/regimen exceptions are not prospectively isolated; Θ requires predictive response performance and Ω requires necessity and sufficiency, which nonhormonal relief directly challenges for any exclusive replacement model. No deliberate universal-aging RCT is demanded. The generic hard-endpoint therapeutic equivalent is available in prevention trials, but null or harmful prevention results do not positively support that hypothesis. GnRH suppression is an imposed intervention, not a natural experiment; no genetic instrument or fully blinded withdrawal-and-rechallenge line is asserted." }, { "kind": "natural_experiment", "available": false, "why_not_sufficient": "The upper ladder is reachable for direct human clinical claims after the declared phenotype adaptation. Replicated symptomatic hormone intervention and an independently instrumented thermoregulatory prediction permit Ζ, with suppression/withdrawal complementary context. Η is held because the complete mediator dependency and major age/regimen exceptions are not prospectively isolated; Θ requires predictive response performance and Ω requires necessity and sufficiency, which nonhormonal relief directly challenges for any exclusive replacement model. No deliberate universal-aging RCT is demanded. The generic hard-endpoint therapeutic equivalent is available in prevention trials, but null or harmful prevention results do not positively support that hypothesis. GnRH suppression is an imposed intervention, not a natural experiment; no genetic instrument or fully blinded withdrawal-and-rechallenge line is asserted." }, { "kind": "dose_response_across_populations", "available": false, "why_not_sufficient": "The upper ladder is reachable for direct human clinical claims after the declared phenotype adaptation. Replicated symptomatic hormone intervention and an independently instrumented thermoregulatory prediction permit Ζ, with suppression/withdrawal complementary context. Η is held because the complete mediator dependency and major age/regimen exceptions are not prospectively isolated; Θ requires predictive response performance and Ω requires necessity and sufficiency, which nonhormonal relief directly challenges for any exclusive replacement model. No deliberate universal-aging RCT is demanded. The generic hard-endpoint therapeutic equivalent is available in prevention trials, but null or harmful prevention results do not positively support that hypothesis. GnRH suppression is an imposed intervention, not a natural experiment; no genetic instrument or fully blinded withdrawal-and-rechallenge line is asserted." }, { "kind": "withdrawal_rechallenge", "available": false, "why_not_sufficient": "The upper ladder is reachable for direct human clinical claims after the declared phenotype adaptation. Replicated symptomatic hormone intervention and an independently instrumented thermoregulatory prediction permit Ζ, with suppression/withdrawal complementary context. Η is held because the complete mediator dependency and major age/regimen exceptions are not prospectively isolated; Θ requires predictive response performance and Ω requires necessity and sufficiency, which nonhormonal relief directly challenges for any exclusive replacement model. No deliberate universal-aging RCT is demanded. The generic hard-endpoint therapeutic equivalent is available in prevention trials, but null or harmful prevention results do not positively support that hypothesis. GnRH suppression is an imposed intervention, not a natural experiment; no genetic instrument or fully blinded withdrawal-and-rechallenge line is asserted." }, { "kind": "therapeutic_perturbation_hard_endpoint", "available": true, "why_not_sufficient": "The upper ladder is reachable for direct human clinical claims after the declared phenotype adaptation. Replicated symptomatic hormone intervention and an independently instrumented thermoregulatory prediction permit Ζ, with suppression/withdrawal complementary context. Η is held because the complete mediator dependency and major age/regimen exceptions are not prospectively isolated; Θ requires predictive response performance and Ω requires necessity and sufficiency, which nonhormonal relief directly challenges for any exclusive replacement model. No deliberate universal-aging RCT is demanded. The generic hard-endpoint therapeutic equivalent is available in prevention trials, but null or harmful prevention results do not positively support that hypothesis. GnRH suppression is an imposed intervention, not a natural experiment; no genetic instrument or fully blinded withdrawal-and-rechallenge line is asserted." } ], "convergence_present": true, "cap_reapplied_to_convergent_set": false }, "provenance_header": { "sources_total": 64, "claims_total": 70, "claims_verified": 70, "claims_unverified": 0, "claims_contradicted": 0, "tier_a_sources": 64, "generated_by": "Codex; HSEF v5.3", "gate_passed": true }, "claims": [ { "id": "C1", "text": "A pooled Europe/China randomized dataset shows fewer hot flushes with ultra-low estradiol/dydrogesterone than placebo. Pooled report includes the Chinese parent trial; not an independent new intervention or long-term safety test.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 1 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C2", "text": "Randomized oral estradiol at two doses reduced hot-flush frequency compared with placebo over twelve weeks. Selected clinical trial populations and short follow-up do not establish cardiovascular or dementia prevention.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 2 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C3", "text": "Two placebo-controlled oral estradiol acetate trials show dose-dependent timing and magnitude of symptom relief. Two trials share formulation and diary instruments; higher dose does not prove all-regimen superiority or safety.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 3 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C4", "text": "A Chinese randomized trial shows ultra-low estradiol/dydrogesterone reduces daily hot flushes more than placebo. Placebo improved substantially; twelve-week symptom benefit is not disease prevention.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 4 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C5", "text": "PEPI hormone regimens reduce vasomotor symptoms while anxiety, cognitive and affective checklist outcomes show no treatment difference. Multiple hormone regimens belong to one parent trial and symptom instruments cannot establish dementia prevention.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 5 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C6", "text": "Randomized transdermal estradiol produced exposure-dependent hot-flush suppression at tested doses. Small early trial and regression predictions are not validated individual response thresholds or long-term safety evidence.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 6 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C7", "text": "REPLENISH participants reported improved menopause-specific quality of life and vasomotor domain scores with several oral estradiol/progesterone doses. Secondary outcomes and correlations do not prove mediation; this is the same parent trial as its sleep report.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 7 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C8", "text": "REPLENISH oral estradiol/progesterone improved several self-reported sleep outcomes compared with placebo. Sleep was secondary and subjective; improvements do not establish all sleep disorders are hormone mediated.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 8 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C9", "text": "WHI combined therapy relieved vasomotor symptoms in younger symptomatic women but did not improve general quality of life meaningfully overall. Older prevention cohort differs from modern symptom-selected users; several endpoints and subgroups require caution.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 9 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C10", "text": "A small single-blind trial improved menopausal symptoms without measured polysomnographic sleep improvement. Limited size and single blinding constrain inference; symptom relief need not normalize every sleep parameter.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 10 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C11", "text": "SMART pooled minority/white subgroup analyses show symptom improvement with conjugated estrogens/bazedoxifene. Post hoc pooling and modest minority representation do not establish ethnic equivalence or independent replication per report.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 11 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C12", "text": "Former WHI combined-hormone users reported more vasomotor symptoms after study-pill cessation than former placebo users. Selected continuing users and post-stop unblinding limit causal withdrawal inference and independence from WHI allocation.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 12 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C13", "text": "Some older women have persistent hot flushes, associated with baseline clinical factors but not measured estradiol concentration. Observational associations do not isolate withdrawal causality or identify an outcome-independent hormone responder group.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 13 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C14", "text": "Extended WHI analyses retain vasomotor benefit but divergent clinical risks and benefits; neither regimen improved overall mortality. Two parent randomized trials generate many reports; oral CEE regimens cannot be transferred wholesale to other routes or younger indications.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 14 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:METHODS:paragraph0, 1:METHODS:paragraph2, 2:RESULTS:paragraph24, 2:RESULTS:paragraph27, 2:RESULTS:paragraph29, 2:RESULTS:paragraph35, 2:RESULTS:paragraph37. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C15", "text": "The WHI symptom/CVD secondary analysis reports age- and regimen-dependent clinical and symptom effects. Two attached corrections concern text/supplement and Figure 3; quantitative reliance is withheld pending their details, and subgroup analyses are not new trials.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 15 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C16", "text": "WHIMS-MRI found no significant hormone-allocation difference in ischemic lesion volumes despite clinical cognitive concerns. Post-trial MRI participants were selected; this proxy null neither proves brain protection nor explains every dementia mechanism.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 16 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C17", "text": "WISDOM found more cardiovascular and thromboembolic events with combined therapy started many years after menopause. Premature closure and brief follow-up limit cancer, dementia and early-initiation conclusions.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 17 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C18", "text": "ADORE found improved satisfying sexual events, desire and distress with a testosterone patch in naturally menopausal HSDD women. Selected diagnosed HSDD and six-month outcomes do not establish general cognition, energy or long-term safety benefit.", "carries_number": false, "load_bearing_for": [ "SC4" ], "source_ns": [ 18 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C19", "text": "APHRODITE found modest sexual-function benefit at the higher tested testosterone patch dose in postmenopausal HSDD women without estrogen. Lower dose missed the event-frequency endpoint; androgenic events increased and rare breast outcomes cannot settle long-term risk.", "carries_number": false, "load_bearing_for": [ "SC4" ], "source_ns": [ 19 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C20", "text": "A randomized patch trial improved sexual activity, desire and distress after surgical menopause with concomitant estrogen. The indicated population and short exposure do not establish nonspecific enhancement or lifelong safety.", "carries_number": false, "load_bearing_for": [ "SC4" ], "source_ns": [ 20 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C21", "text": "INTIMATE SM1 improved satisfying sexual activity and desire and reduced distress versus placebo after surgical menopause. Patient-reported endpoints, concurrent estrogen and sponsor-related trial platform constrain mechanistic independence.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 21 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C22", "text": "INTIMATE NM1 reported improved sexual events, desire and distress in naturally menopausal HSDD women taking estrogen. An attached erratum is recorded without identifier; baseline SHBG analytic restriction and short follow-up limit inference.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 22 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C23", "text": "Open-label extensions reported no major worsening of common safety measures during testosterone patch exposure. Selected continuing participants and lack of randomized long-term comparator cannot exclude rare breast or cardiovascular harm.", "carries_number": false, "load_bearing_for": [ "SC4" ], "source_ns": [ 23 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C24", "text": "A testosterone cream crossover trial improved sexual domains in HSDD women but not mood or energy. Small sample, concurrent estrogen and crossover limitations do not establish broad cognitive or muscle benefit.", "carries_number": false, "load_bearing_for": [ "SC4", "SC5" ], "source_ns": [ 24 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C25", "text": "An interviewed subset of two testosterone trials reported meaningful sexual benefit more often on active patches. Selected interviews and responder analyses are not an independent trial or a baseline definition of who benefits.", "carries_number": false, "load_bearing_for": [ "SC4" ], "source_ns": [ 25 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C26", "text": "Testosterone patch improved desire with transdermal estrogen after oophorectomy, while the sexual-event endpoint was not significant. Small sample and incomplete retention limit precision; author-name correction is attached and not a new source.", "carries_number": false, "load_bearing_for": [ "SC4" ], "source_ns": [ 26 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C27", "text": "A dose-ranging patch trial found sexual-domain benefit at an intermediate dose, with lower-dose nulls and no consistent monotonic response. Substantial attrition and marginal endpoint significance weaken precise dose-response prediction.", "carries_number": false, "load_bearing_for": [ "SC4" ], "source_ns": [ 27 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C28", "text": "A retrospective menopause-clinic cohort reported mood and cognitive symptom improvement after testosterone addition. No randomized comparator; expectation, regression, concurrent HRT and selective treatment seeking prevent causal generalization.", "carries_number": false, "load_bearing_for": [ "SC5" ], "source_ns": [ 28 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C29", "text": "A surgical-menopause crossover trial found no cognitive-fatigue benefit from testosterone added to estrogen. Small sample and a specific oral regimen cannot exclude every formulation effect; same parent as memory analysis.", "carries_number": false, "load_bearing_for": [ "SC5" ], "source_ns": [ 29 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C30", "text": "Testosterone added to estrogen worsened immediate verbal memory while other memory outcomes were unaffected. Small surgical-menopause trial and multiple domains do not prove all testosterone regimens impair cognition.", "carries_number": false, "load_bearing_for": [ "SC5" ], "source_ns": [ 30 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C31", "text": "A randomized transdermal testosterone trial improved its verbal-learning task but not other cognitive domains or general wellbeing. One modest task-specific signal is neither prevention of dementia nor evidence of generalized energy and muscle benefits.", "carries_number": false, "load_bearing_for": [ "SC5" ], "source_ns": [ 31 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C32", "text": "A randomized estrogen/testosterone/placebo trial found no substantial four-week differences in verbal or spatial cognition. Short duration and oral regimens do not settle longer transdermal exposure or dementia endpoints.", "carries_number": false, "load_bearing_for": [ "SC5" ], "source_ns": [ 32 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C33", "text": "Secondary hormone-level analyses found domain-specific associations in the same randomized cohort. Correlations among post-treatment hormones and scores do not manipulate a mediator or add an independent efficacy trial.", "carries_number": false, "load_bearing_for": [ "SC5" ], "source_ns": [ 33 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C34", "text": "A testosterone dose-ranging trial found no benefit across tested cognitive domains over twenty-four weeks despite verified exposure. Only participants with complete cognitive data were analyzed; small dose groups limit precision and share a parent with muscle outcomes.", "carries_number": false, "load_bearing_for": [ "SC5" ], "source_ns": [ 34 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph1, 1:Methods:paragraph2, 1:Methods:paragraph4, 2:Results:paragraph0, 2:Results:paragraph3. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C35", "text": "Aromatase inhibition did not alter cognition in estrogen-treated women receiving testosterone in both randomized arms. Without a testosterone-free randomized arm, within-group improvement cannot establish testosterone efficacy.", "carries_number": false, "load_bearing_for": [ "SC5" ], "source_ns": [ 35 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C36", "text": "Randomized estradiol raised sweating threshold and reduced objectively recorded laboratory hot flashes compared with placebo. Small physiological trial narrows diary expectation but does not prove the complete estrogen–KNDy mediator sequence or all individual responses.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 36 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C37", "text": "Controlled heating/cooling and exercise showed narrowed thermoregulatory zones and heat-triggered flushing in symptomatic women. Exposure groups were not randomized for estrogen deficiency; this is thermoregulatory discrimination, not proof estrogen alone causes all symptoms.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 37 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C38", "text": "Symptomatic women had lower sweating thresholds and greater sweat rates than asymptomatic/eumenorrheic groups despite similar explanatory hormone levels. Small nonrandomized groups support a thermoregulatory phenotype but not an exclusive sex-steroid cause.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 38 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C39", "text": "GnRH agonist-induced ovarian suppression produced new hot flashes, with objective and subjective sleep effects differing by measurement. Uncontrolled induction and post-outcome symptom grouping do not isolate estrogen from all GnRH effects or prove every sleep problem is vasomotor.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 39 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C40", "text": "A GnRH-agonist model associated induced nighttime hot flashes with greater polysomnographic sleep fragmentation. Within-experiment symptom correlations are not an independently randomized mediator; related clinical protocol may share participants and instruments.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 40 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C41", "text": "Induced hypogonadism increased nighttime hot flashes and disturbed sleep but rarely clinically significant depressive symptoms in screened healthy women. No placebo induction group; psychiatric-history exclusions prevent transfer to women with prior mood disorders.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 41 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C42", "text": "Blinded neurokinin-B infusion caused flushing with objective heat-dissipation changes in healthy women without measured estradiol change. Exogenous challenge is a pathway sufficiency test, not proof hormone withdrawal or endogenous NKB is necessary in every menopausal flush.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 42 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 0:Methods:paragraph2, 0:Methods:paragraph5, 0:Methods:paragraph6, 1:Results:paragraph3, 1:Results:paragraph4, 1:Results:paragraph7. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C43", "text": "A blinded NK3-antagonist crossover trial reduced menopausal hot-flush frequency compared with placebo. Small sample, incomplete completion and liver-enzyme elevations limit broad efficacy and safety predictions; it tests a nonhormonal pathway.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 43 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C44", "text": "An acute kappa-agonist pilot reduced hot-flash frequency relative to placebo in a small crossover sample. Very small analyzed group, acute exposure and opioid subjective effects limit blinding and long-term causal interpretation.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 44 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C45", "text": "SKYLIGHT1 found reduced vasomotor frequency/severity with fezolinetant at tested doses during its placebo-controlled interval. Nonhormonal efficacy does not prove systemic MHT prevention or necessity; later extension lacks ongoing placebo comparison.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 45 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C46", "text": "OASIS3 elinzanetant reduced its prespecified twelve-week vasomotor-frequency endpoint; later symptoms favored treatment descriptively. Longer secondary/exploratory endpoints were not powered confirmatory tests, and treatment-related adverse events were more frequent.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 46 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph1, 1:Methods:paragraph4, 1:Methods:paragraph8, 2:Results:paragraph10, 2:Results:paragraph11, 2:Results:paragraph13. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C47", "text": "SKYLIGHT2 reproduced fezolinetant vasomotor-frequency and severity benefits during placebo-controlled treatment. Same pharmacological class and diary platform are replication rather than a new independent causal modality.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 47 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C48", "text": "SKYLIGHT4 characterized one-year endometrial, liver and bone safety under randomized fezolinetant exposure. Safety-focused endpoints are not evidence of estrogen replacement efficacy or an assurance against rare postmarketing liver injury.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 48 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C49", "text": "DAYLIGHT reduced hot-flush frequency/severity and sleep disturbance in women considered unsuitable for hormone therapy. Most participants were averse or caution categories rather than contraindicated; attached correction and finite follow-up constrain safety generalization.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 49 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C50", "text": "MOONLIGHTI found no significant vasomotor-frequency or severity advantage for the tested fezolinetant dose in East Asian women. A regimen/context null restricts generalization but does not erase positive trials at other doses or populations.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 50 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C51", "text": "VESTA dose-ranging NK3 blockade improved vasomotor frequency at tested doses and severity at some regimens. Multiple dose arms share one study; diary responses and variable severity results constrain precise prediction.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 51 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C52", "text": "A fezolinetant phase2a placebo-controlled trial reduced vasomotor score and reported frequency. Small selected cohort and one regimen do not establish universal response or lifetime safety.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 52 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C53", "text": "WHI combined oral CEE/MPA had an unfavorable overall prevention risk–benefit balance despite fracture benefits. Regimen and enrollment ages matter; results do not refute symptom efficacy or establish the risk of every modern formulation.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 53 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C54", "text": "WHI CEE-alone increased stroke risk, reduced hip fractures and did not demonstrate coronary prevention or overall net benefit. Hysterectomy cohort and oral CEE cannot be treated as the same population/regimen as combined therapy.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 54 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C55", "text": "WHIMS combined therapy increased probable dementia in women enrolled aged at least sixty-five and did not prevent mild cognitive impairment. Age and CEE/MPA regimen limit extrapolation to early-menopause modern therapy; dementia is distinct from acute cognitive tests.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 55 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C56", "text": "WHIMS estrogen-alone did not reduce dementia or mild cognitive impairment, and pooled trials showed increased risk. The estrogen-alone dementia estimate was imprecise; pooled WHI reports are not extra independent studies.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 56 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C57", "text": "ELITE slowed carotid intima-media progression only with early estradiol initiation, without corresponding coronary CT differences. Surrogate progression and sparse clinical events do not establish net cardiovascular or dementia prevention.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 57 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 0:METHODS:paragraph0, 0:METHODS:paragraph2, 0:METHODS:paragraph5, 0:METHODS:paragraph6, 1:RESULTS:paragraph2, 1:RESULTS:paragraph3, 1:RESULTS:paragraph6. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C58", "text": "ELITE cognitive outcomes showed no verbal-memory, executive or global-cognition benefit with early or later estradiol initiation. Several years of cognitive tests cannot exclude later dementia prevention; same parent as the vascular report.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 58 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C59", "text": "KEEPS showed vasomotor relief but no cognitive benefit; oral CEE improved selected mood scores while transdermal estradiol did not. Cognitively healthy low-risk recent-menopause users, attrition and finite horizon constrain disease-prevention inference.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 59 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph4, 1:Methods:paragraph6, 1:Methods:paragraph8, 1:Methods:paragraph22, 2:Results:paragraph1, 2:Results:paragraph4, 2:Results:paragraph12, 2:Results:paragraph14. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C60", "text": "Large Medicare analyses associate certain hormone formulations/routes with lower mortality and selected disease risks after age sixty-five. Healthy-user, prescribing, continuation and confounding-by-indication effects remain; sample size does not randomize exposure.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 60 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C61", "text": "MsFLASH randomized estradiol and venlafaxine both reduced bothersome vasomotor frequency more than placebo. The between-active-treatment contrast was imprecise; short follow-up cannot establish general hormone superiority or disease prevention.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 61 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:METHODS:paragraph0, 1:METHODS:paragraph3, 1:METHODS:paragraph6, 1:METHODS:paragraph8, 2:RESULTS:paragraph1, 2:RESULTS:paragraph2, 2:RESULTS:paragraph3. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C62", "text": "REPLENISH tested oral estradiol/progesterone versus placebo and found vasomotor-frequency/severity benefit at several doses. Dose-specific coprimary results and finite endometrial analysis population do not prove zero lifetime risk; attached correction details require separate checking.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 62 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C63", "text": "Testosterone dose-ranging produced lean-mass and selected muscle-power gains mainly at supraphysiologic exposure, with several physical-function tests unchanged. Small dose groups, secondary outcomes and late trial registration limit prediction; high-dose gains cannot establish physiological replacement benefit.", "carries_number": false, "load_bearing_for": [ "SC5" ], "source_ns": [ 63 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:METHODS:paragraph0, 1:METHODS:paragraph1, 1:METHODS:paragraph3, 1:METHODS:paragraph6, 1:METHODS:paragraph7, 2:RESULTS:paragraph3, 2:RESULTS:paragraph6, 2:RESULTS:paragraph7, 3:DISCUSSION:paragraph1, 3:DISCUSSION:paragraph4. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C64", "text": "The same testosterone dose-response parent trial found no major changes in measured cardiometabolic risk markers. Marker stability over a short interval cannot exclude clinical cardiovascular harms or establish metabolic prevention.", "carries_number": false, "load_bearing_for": [ "SC5" ], "source_ns": [ 64 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "CSC1", "text": "Hormone suppression and replacement, a predicted thermoregulatory response under randomized estradiol and mechanistically distinct NKB challenge/blockade support a causal endocrine–thermoregulatory contribution. Deficiency alone does not predict all symptoms; objective pathway tests and symptomatic/asymptomatic comparisons preserve this boundary. Ζ is contribution, not sole-cause necessity.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 6, 12, 13, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-13", "note": "" }, { "id": "CSC2", "text": "Repeated blinded hormone trials show symptom relief beyond placebo in baseline symptomatic women, including oral and transdermal regimens. MsFLASH provides an active nonhormonal comparison; objective sweating-threshold/flush experiments reduce a reporting-only explanation, and withdrawal observations agree with reversible control. Ζ reflects complementary failure structures; replication/report counts alone do not provide independence. Η would require stronger mediator isolation and prospective cross-context control of major exceptions.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 15, 36, 59, 61, 62 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-13", "note": "" }, { "id": "CSC3", "text": "Net cardiovascular or neurodegenerative prevention does not inherit symptom efficacy. WHI/WHIMS and WISDOM supply direct regimen/age-specific clinical contradictions, while early ELITE CIMT and Medicare associations leave a narrower preventive possibility open. Positive surrogate/observational support is insufficient for hard prevention; the functional contradiction downgrades that supportive Γ-level route to Β. It is not a blanket claim all formulations or early symptomatic use are harmful.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 5, 9, 14, 15, 16, 17, 53, 54, 55, 56, 57, 58, 59, 60 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-13", "note": "" }, { "id": "CSC4", "text": "Testosterone patch trials establish a modest causal sexual-function benefit in baseline diagnosed postmenopausal HSDD, with limits across dose, concurrent estrogen and endpoints. These replicated, closely related intervention platforms do not supply a separate orthogonal causal mechanism or all-women indication; Ε preserves the mapped clinical context and finite safety horizon.", "carries_number": false, "load_bearing_for": [ "SC4" ], "source_ns": [ 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-13", "note": "" }, { "id": "CSC5", "text": "One verbal-learning outcome and high-exposure muscle/performance signals provide narrower clinical positives; these are retained with their doses and populations. They do not establish the bundled general cognition, energy and muscle proposition in women without HSDD. Multiple cognitive domains and wellbeing/fatigue outcomes are null. The full enhancement proposition retains partial support at Γ; this does not deny the separate HSDD clinical efficacy or the isolated task finding.", "carries_number": false, "load_bearing_for": [ "SC5" ], "source_ns": [ 24, 28, 29, 30, 31, 32, 33, 34, 35, 63, 64 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-13", "note": "" }, { "id": "CH", "text": "Systemic menopausal hormone therapy reduces bothersome hot flushes; this established symptom benefit does not demonstrate dementia or cardiovascular prevention, and testosterone needs its own indication-specific evidence.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 61, 36, 14, 55, 19, 34 ], "verification": "verified", "verified_against": "Bounded synthesis of examined sources; score is adjudication.", "verified_on": "2026-10-13", "note": "" } ], "citation_ledger": [ { "n": 1, "citation": "Stevenson JC, Ren M, Kahler E et al. Ultra-low dose estradiol and dydrogesterone for the treatment of menopausal symptoms in a pooled, multi-ethnic population. Maturitas. 2024.", "tier": "A", "kind": "rct", "pmid": "39317030", "doi": "10.1016/j.maturitas.2024.108117", "url": "https://pubmed.ncbi.nlm.nih.gov/39317030/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "UltraLow-E2Dydrogesterone-China-CTR20160689", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C1", "CSC2" ] }, { "n": 2, "citation": "Notelovitz M, Mattox JH. Suppression of vasomotor and vulvovaginal symptoms with continuous oral 17beta-estradiol. Menopause (New York, N.Y.). 2000.", "tier": "A", "kind": "rct", "pmid": "10993030", "doi": "10.1097/00042192-200007050-00005", "url": "https://pubmed.ncbi.nlm.nih.gov/10993030/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID10993030", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C2", "CSC2" ] }, { "n": 3, "citation": "Speroff L, Haney AF, Gilbert RD et al. Efficacy of a new, oral estradiol acetate formulation for relief of menopause symptoms. Menopause (New York, N.Y.). 2006.", "tier": "A", "kind": "rct", "pmid": "16735941", "doi": "10.1097/01.gme.0000182802.06762.b2", "url": "https://pubmed.ncbi.nlm.nih.gov/16735941/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID16735941", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C3", "CSC2" ] }, { "n": 4, "citation": "Ren M, Ruan X, Gu L et al. Ultra-low-dose estradiol and dydrogesterone: a phase III study for vasomotor symptoms in China. Climacteric : the journal of the International Menopause Society. 2022.", "tier": "A", "kind": "rct", "pmid": "34402360", "doi": "10.1080/13697137.2021.1956894", "url": "https://pubmed.ncbi.nlm.nih.gov/34402360/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "UltraLow-E2Dydrogesterone-China-CTR20160689", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C4", "CSC2" ] }, { "n": 5, "citation": "Greendale GA, Reboussin BA, Hogan P et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstetrics and gynecology. 1998.", "tier": "A", "kind": "rct", "pmid": "9840563", "doi": "10.1016/s0029-7844(98)00305-6", "url": "https://pubmed.ncbi.nlm.nih.gov/9840563/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID9840563", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C5", "CSC2", "CSC3" ] }, { "n": 6, "citation": "Steingold KA, Laufer L, Chetkowski RJ et al. Treatment of hot flashes with transdermal estradiol administration. The Journal of clinical endocrinology and metabolism. 1985.", "tier": "A", "kind": "rct", "pmid": "3928674", "doi": "10.1210/jcem-61-4-627", "url": "https://pubmed.ncbi.nlm.nih.gov/3928674/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID3928674", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C6", "CSC1", "CSC2" ] }, { "n": 7, "citation": "Simon JA, Kaunitz AM, Kroll R et al. Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms. Menopause (New York, N.Y.). 2019.", "tier": "A", "kind": "rct", "pmid": "30489424", "doi": "10.1097/GME.0000000000001271", "url": "https://pubmed.ncbi.nlm.nih.gov/30489424/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "REPLENISH-NCT01942668", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C7", "CSC2" ] }, { "n": 8, "citation": "Kagan R, Constantine G, Kaunitz AM et al. Improvement in sleep outcomes with a 17β-estradiol-progesterone oral capsule (TX-001HR) for postmenopausal women. Menopause (New York, N.Y.). 2018.", "tier": "A", "kind": "rct", "pmid": "30586005", "doi": "10.1097/GME.0000000000001278", "url": "https://pubmed.ncbi.nlm.nih.gov/30586005/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "REPLENISH-NCT01942668", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C8", "CSC2" ] }, { "n": 9, "citation": "Hays J, Ockene JK, Brunner RL et al. Effects of estrogen plus progestin on health-related quality of life. The New England journal of medicine. 2003.", "tier": "A", "kind": "rct", "pmid": "12642637", "doi": "10.1056/NEJMoa030311", "url": "https://pubmed.ncbi.nlm.nih.gov/12642637/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "WHI-EplusP", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C9", "CSC2", "CSC3" ] }, { "n": 10, "citation": "Purdie DW, Empson JA, Crichton C et al. Hormone replacement therapy, sleep quality and psychological wellbeing. British journal of obstetrics and gynaecology. 1995.", "tier": "A", "kind": "rct", "pmid": "7547766", "doi": "10.1111/j.1471-0528.1995.tb11433.x", "url": "https://pubmed.ncbi.nlm.nih.gov/7547766/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID7547766", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C10", "CSC2" ] }, { "n": 11, "citation": "Pinkerton JV, Pickar JH, Ryan KA et al. Conjugated estrogens and bazedoxifene in minority populations: pooled analysis of four phase 3 trials. Menopause (New York, N.Y.). 2016.", "tier": "A", "kind": "rct", "pmid": "27163519", "doi": "10.1097/GME.0000000000000617", "url": "https://pubmed.ncbi.nlm.nih.gov/27163519/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID27163519", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C11", "CSC2" ] }, { "n": 12, "citation": "Ockene JK, Barad DH, Cochrane BB et al. Symptom experience after discontinuing use of estrogen plus progestin. JAMA. 2005.", "tier": "A", "kind": "primary", "pmid": "16014592", "doi": "10.1001/jama.294.2.183", "url": "https://pubmed.ncbi.nlm.nih.gov/16014592/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "WHI-EplusP", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C12", "CSC1", "CSC2" ] }, { "n": 13, "citation": "Huang AJ, Grady D, Jacoby VL et al. Persistent hot flushes in older postmenopausal women. Archives of internal medicine. 2008.", "tier": "A", "kind": "primary", "pmid": "18443259", "doi": "10.1001/archinte.168.8.840", "url": "https://pubmed.ncbi.nlm.nih.gov/18443259/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID18443259", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C13", "CSC1" ] }, { "n": 14, "citation": "Manson JE, Chlebowski RT, Stefanick ML et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013.", "tier": "A", "kind": "rct", "pmid": "24084921", "doi": "10.1001/jama.2013.278040", "url": "https://pubmed.ncbi.nlm.nih.gov/24084921/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "WHI-two-parent-trials", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:METHODS:paragraph0, 1:METHODS:paragraph2, 2:RESULTS:paragraph24, 2:RESULTS:paragraph27, 2:RESULTS:paragraph29, 2:RESULTS:paragraph35, 2:RESULTS:paragraph37. No complete-paper or supplement audit claimed.", "carries_claims": [ "C14", "CSC2", "CSC3", "CH" ] }, { "n": 15, "citation": "Rossouw JE, Aragaki AK, Manson JE et al. Menopausal Hormone Therapy and Cardiovascular Diseases in Women With Vasomotor Symptoms: A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trials. JAMA internal medicine. 2025.", "tier": "A", "kind": "rct", "pmid": "40952729", "doi": "10.1001/jamainternmed.2025.4510", "url": "https://pubmed.ncbi.nlm.nih.gov/40952729/", "status_flags": [ "ErratumIn: PMID41182785", "ErratumIn: PMID41396618" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "WHI-two-parent-trials", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C15", "CSC2", "CSC3" ] }, { "n": 16, "citation": "Coker LH, Hogan PE, Bryan NR et al. Postmenopausal hormone therapy and subclinical cerebrovascular disease: the WHIMS-MRI Study. Neurology. 2009.", "tier": "A", "kind": "rct", "pmid": "19139363", "doi": "10.1212/01.wnl.0000339036.88842.9e", "url": "https://pubmed.ncbi.nlm.nih.gov/19139363/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "WHI-two-parent-trials", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C16", "CSC3" ] }, { "n": 17, "citation": "Vickers MR, MacLennan AH, Lawton B et al. Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ (Clinical research ed.). 2007.", "tier": "A", "kind": "rct", "pmid": "17626056", "doi": "10.1136/bmj.39266.425069.AD", "url": "https://pubmed.ncbi.nlm.nih.gov/17626056/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID17626056", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C17", "CSC3" ] }, { "n": 18, "citation": "Panay N, Al-Azzawi F, Bouchard C et al. Testosterone treatment of HSDD in naturally menopausal women: the ADORE study. Climacteric : the journal of the International Menopause Society. 2010.", "tier": "A", "kind": "rct", "pmid": "20166859", "doi": "10.3109/13697131003675922", "url": "https://pubmed.ncbi.nlm.nih.gov/20166859/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID20166859", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C18", "CSC4" ] }, { "n": 19, "citation": "Davis SR, Moreau M, Kroll R et al. Testosterone for low libido in postmenopausal women not taking estrogen. The New England journal of medicine. 2008.", "tier": "A", "kind": "rct", "pmid": "18987368", "doi": "10.1056/NEJMoa0707302", "url": "https://pubmed.ncbi.nlm.nih.gov/18987368/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID18987368", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C19", "CSC4", "CH" ] }, { "n": 20, "citation": "Buster JE, Kingsberg SA, Aguirre O et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstetrics and gynecology. 2005.", "tier": "A", "kind": "rct", "pmid": "15863529", "doi": "10.1097/01.AOG.0000158103.27672.0d", "url": "https://pubmed.ncbi.nlm.nih.gov/15863529/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "INTIMATE-SM2", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C20", "CSC4" ] }, { "n": 21, "citation": "Simon J, Braunstein G, Nachtigall L et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. The Journal of clinical endocrinology and metabolism. 2005.", "tier": "A", "kind": "rct", "pmid": "16014407", "doi": "10.1210/jc.2004-1747", "url": "https://pubmed.ncbi.nlm.nih.gov/16014407/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "INTIMATE-SM1", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C21", "CSC4" ] }, { "n": 22, "citation": "Shifren JL, Davis SR, Moreau M et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. Menopause (New York, N.Y.). 2006.", "tier": "A", "kind": "rct", "pmid": "16932240", "doi": "10.1097/01.gme.0000243567.32828.99", "url": "https://pubmed.ncbi.nlm.nih.gov/16932240/", "status_flags": [ "ErratumIn: PMID not supplied" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID16932240", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C22", "CSC4" ] }, { "n": 23, "citation": "Nachtigall L, Casson P, Lucas J et al. Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2011.", "tier": "A", "kind": "rct", "pmid": "21142609", "doi": "10.3109/09513590.2010.487597", "url": "https://pubmed.ncbi.nlm.nih.gov/21142609/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "INTIMATE-surgical-pooled-parent-reports", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C23", "CSC4" ] }, { "n": 24, "citation": "El-Hage G, Eden JA, Manga RZ. A double-blind, randomized, placebo-controlled trial of the effect of testosterone cream on the sexual motivation of menopausal hysterectomized women with hypoactive sexual desire disorder. Climacteric : the journal of the International Menopause Society. 2007.", "tier": "A", "kind": "rct", "pmid": "17653960", "doi": "10.1080/13697130701364644", "url": "https://pubmed.ncbi.nlm.nih.gov/17653960/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID17653960", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C24", "CSC4", "CSC5" ] }, { "n": 25, "citation": "Kingsberg S, Shifren J, Wekselman K et al. Evaluation of the clinical relevance of benefits associated with transdermal testosterone treatment in postmenopausal women with hypoactive sexual desire disorder. The journal of sexual medicine. 2007.", "tier": "A", "kind": "rct", "pmid": "17627745", "doi": "10.1111/j.1743-6109.2007.00526.x", "url": "https://pubmed.ncbi.nlm.nih.gov/17627745/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "INTIMATE-surgical-pooled-parent-reports", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C25", "CSC4" ] }, { "n": 26, "citation": "Davis SR, van der Mooren MJ, van Lunsen RH et al. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Menopause (New York, N.Y.). 2006.", "tier": "A", "kind": "rct", "pmid": "16735935", "doi": "10.1097/01.gme.0000179049.08371.c7", "url": "https://pubmed.ncbi.nlm.nih.gov/16735935/", "status_flags": [ "ErratumIn: PMID not supplied" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID16735935", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C26", "CSC4" ] }, { "n": 27, "citation": "Braunstein GD, Sundwall DA, Katz M et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Archives of internal medicine. 2005.", "tier": "A", "kind": "rct", "pmid": "16043675", "doi": "10.1001/archinte.165.14.1582", "url": "https://pubmed.ncbi.nlm.nih.gov/16043675/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID16043675", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C27", "CSC4" ] }, { "n": 28, "citation": "Glynne S, Kamal A, Kamel AM et al. Effect of transdermal testosterone therapy on mood and cognitive symptoms in peri- and postmenopausal women: a pilot study. Archives of women's mental health. 2025.", "tier": "A", "kind": "primary", "pmid": "39283522", "doi": "10.1007/s00737-024-01513-6", "url": "https://pubmed.ncbi.nlm.nih.gov/39283522/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID39283522", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C28", "CSC5" ] }, { "n": 29, "citation": "Möller MC, Rådestad AF, von Schoultz B et al. Effect of estrogen and testosterone replacement therapy on cognitive fatigue. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2013.", "tier": "A", "kind": "rct", "pmid": "23095007", "doi": "10.3109/09513590.2012.730568", "url": "https://pubmed.ncbi.nlm.nih.gov/23095007/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "Testosterone-estrogen-oophorectomy-50women", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C29", "CSC5" ] }, { "n": 30, "citation": "Möller MC, Bartfai AB, Rådestad AF. Effects of testosterone and estrogen replacement on memory function. Menopause (New York, N.Y.). 2010.", "tier": "A", "kind": "rct", "pmid": "20555288", "doi": "10.1097/gme.0b013e3181dc2e40", "url": "https://pubmed.ncbi.nlm.nih.gov/20555288/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "Testosterone-estrogen-oophorectomy-50women", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C30", "CSC5" ] }, { "n": 31, "citation": "Davis SR, Jane F, Robinson PJ et al. Transdermal testosterone improves verbal learning and memory in postmenopausal women not on oestrogen therapy. Clinical endocrinology. 2014.", "tier": "A", "kind": "rct", "pmid": "24716847", "doi": "10.1111/cen.12459", "url": "https://pubmed.ncbi.nlm.nih.gov/24716847/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID24716847", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C31", "CSC5" ] }, { "n": 32, "citation": "Kocoska-Maras L, Zethraeus N, Rådestad AF et al. A randomized trial of the effect of testosterone and estrogen on verbal fluency, verbal memory, and spatial ability in healthy postmenopausal women. Fertility and sterility. 2011.", "tier": "A", "kind": "rct", "pmid": "20667535", "doi": "10.1016/j.fertnstert.2010.05.062", "url": "https://pubmed.ncbi.nlm.nih.gov/20667535/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "Testosterone-estrogen-cognition-200women", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C32", "CSC5" ] }, { "n": 33, "citation": "Kocoska-Maras L, Rådestad AF, Carlström K et al. Cognitive function in association with sex hormones in postmenopausal women. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2013.", "tier": "A", "kind": "primary", "pmid": "22967437", "doi": "10.3109/09513590.2012.705385", "url": "https://pubmed.ncbi.nlm.nih.gov/22967437/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "Testosterone-estrogen-cognition-200women", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C33", "CSC5" ] }, { "n": 34, "citation": "Huang G, Wharton W, Travison TG et al. Effects of testosterone administration on cognitive function in hysterectomized women with low testosterone levels: a dose-response randomized trial. Journal of endocrinological investigation. 2015.", "tier": "A", "kind": "rct", "pmid": "25430996", "doi": "10.1007/s40618-014-0213-3", "url": "https://pubmed.ncbi.nlm.nih.gov/25430996/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "Testosterone-dose-response-NCT00494208", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph1, 1:Methods:paragraph2, 1:Methods:paragraph4, 2:Results:paragraph0, 2:Results:paragraph3. No complete-paper or supplement audit claimed.", "carries_claims": [ "C34", "CSC5", "CH" ] }, { "n": 35, "citation": "Shah S, Bell RJ, Savage G et al. Testosterone aromatization and cognition in women: a randomized, placebo-controlled trial. Menopause (New York, N.Y.). 2006.", "tier": "A", "kind": "rct", "pmid": "16837882", "doi": "10.1097/01.gme.0000227333.50867.4e", "url": "https://pubmed.ncbi.nlm.nih.gov/16837882/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID16837882", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C35", "CSC5" ] }, { "n": 36, "citation": "Freedman RR, Blacker CM. Estrogen raises the sweating threshold in postmenopausal women with hot flashes. Fertility and sterility. 2002.", "tier": "A", "kind": "rct", "pmid": "11872200", "doi": "10.1016/s0015-0282(01)03009-6", "url": "https://pubmed.ncbi.nlm.nih.gov/11872200/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID11872200", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C36", "CSC1", "CSC2", "CH" ] }, { "n": 37, "citation": "Freedman RR, Krell W. Reduced thermoregulatory null zone in postmenopausal women with hot flashes. American journal of obstetrics and gynecology. 1999.", "tier": "A", "kind": "primary", "pmid": "10411797", "doi": "10.1016/s0002-9378(99)70437-0", "url": "https://pubmed.ncbi.nlm.nih.gov/10411797/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID10411797", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C37", "CSC1" ] }, { "n": 38, "citation": "Freedman RR, Subramanian M. Effects of symptomatic status and the menstrual cycle on hot flash-related thermoregulatory parameters. Menopause (New York, N.Y.). 2005.", "tier": "A", "kind": "primary", "pmid": "15772562", "doi": "10.1097/00042192-200512020-00009", "url": "https://pubmed.ncbi.nlm.nih.gov/15772562/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID15772562", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C38", "CSC1" ] }, { "n": 39, "citation": "Joffe H, White DP, Crawford SL et al. Adverse effects of induced hot flashes on objectively recorded and subjectively reported sleep: results of a gonadotropin-releasing hormone agonist experimental protocol. Menopause (New York, N.Y.). 2013.", "tier": "A", "kind": "primary", "pmid": "23481119", "doi": "10.1097/GME.0b013e31828292d1", "url": "https://pubmed.ncbi.nlm.nih.gov/23481119/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID23481119", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C39", "CSC1" ] }, { "n": 40, "citation": "Joffe H, Crawford S, Economou N et al. A gonadotropin-releasing hormone agonist model demonstrates that nocturnal hot flashes interrupt objective sleep. Sleep. 2013.", "tier": "A", "kind": "primary", "pmid": "24293774", "doi": "10.5665/sleep.3244", "url": "https://pubmed.ncbi.nlm.nih.gov/24293774/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID24293774", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C40", "CSC1" ] }, { "n": 41, "citation": "Ben Dor R, Harsh VL, Fortinsky P et al. Effects of pharmacologically induced hypogonadism on mood and behavior in healthy young women. The American journal of psychiatry. 2013.", "tier": "A", "kind": "primary", "pmid": "23545794", "doi": "10.1176/appi.ajp.2012.12010117", "url": "https://pubmed.ncbi.nlm.nih.gov/23545794/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID23545794", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C41", "CSC1" ] }, { "n": 42, "citation": "Jayasena CN, Comninos AN, Stefanopoulou E et al. Neurokinin B administration induces hot flushes in women. Scientific reports. 2015.", "tier": "A", "kind": "rct", "pmid": "25683060", "doi": "10.1038/srep08466", "url": "https://pubmed.ncbi.nlm.nih.gov/25683060/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID25683060", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 0:Methods:paragraph2, 0:Methods:paragraph5, 0:Methods:paragraph6, 1:Results:paragraph3, 1:Results:paragraph4, 1:Results:paragraph7. No complete-paper or supplement audit claimed.", "carries_claims": [ "C42", "CSC1" ] }, { "n": 43, "citation": "Prague JK, Roberts RE, Comninos AN et al. Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2017.", "tier": "A", "kind": "rct", "pmid": "28385352", "doi": "10.1016/S0140-6736(17)30823-1", "url": "https://pubmed.ncbi.nlm.nih.gov/28385352/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID28385352", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C43", "CSC1" ] }, { "n": 44, "citation": "Oakley AE, Steiner RA, Chavkin C et al. κ Agonists as a novel therapy for menopausal hot flashes. Menopause (New York, N.Y.). 2015.", "tier": "A", "kind": "rct", "pmid": "25988798", "doi": "10.1097/GME.0000000000000476", "url": "https://pubmed.ncbi.nlm.nih.gov/25988798/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID25988798", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C44", "CSC1" ] }, { "n": 45, "citation": "Lederman S, Ottery FD, Cano A et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet (London, England). 2023.", "tier": "A", "kind": "rct", "pmid": "36924778", "doi": "10.1016/S0140-6736(23)00085-5", "url": "https://pubmed.ncbi.nlm.nih.gov/36924778/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID36924778", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C45", "CSC1" ] }, { "n": 46, "citation": "Panay N, Joffe H, Maki PM et al. Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: A Phase 3 Randomized Clinical Trial. JAMA internal medicine. 2025.", "tier": "A", "kind": "rct", "pmid": "40920404", "doi": "10.1001/jamainternmed.2025.4421", "url": "https://pubmed.ncbi.nlm.nih.gov/40920404/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID40920404", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph1, 1:Methods:paragraph4, 1:Methods:paragraph8, 2:Results:paragraph10, 2:Results:paragraph11, 2:Results:paragraph13. No complete-paper or supplement audit claimed.", "carries_claims": [ "C46", "CSC1" ] }, { "n": 47, "citation": "Johnson KA, Martin N, Nappi RE et al. Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT. The Journal of clinical endocrinology and metabolism. 2023.", "tier": "A", "kind": "rct", "pmid": "36734148", "doi": "10.1210/clinem/dgad058", "url": "https://pubmed.ncbi.nlm.nih.gov/36734148/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID36734148", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C47", "CSC1" ] }, { "n": 48, "citation": "Neal-Perry G, Cano A, Lederman S et al. Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial. Obstetrics and gynecology. 2023.", "tier": "A", "kind": "rct", "pmid": "36897180", "doi": "10.1097/AOG.0000000000005114", "url": "https://pubmed.ncbi.nlm.nih.gov/36897180/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID36897180", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C48", "CSC1" ] }, { "n": 49, "citation": "Schaudig K, Wang X, Bouchard C et al. Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial. BMJ (Clinical research ed.). 2024.", "tier": "A", "kind": "rct", "pmid": "39557487", "doi": "10.1136/bmj-2024-079525", "url": "https://pubmed.ncbi.nlm.nih.gov/39557487/", "status_flags": [ "ErratumIn: PMID39603693" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID39557487", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C49", "CSC1" ] }, { "n": 50, "citation": "Ruan X, Bai W, Ren M et al. Efficacy and safety of fezolinetant for moderate to severe vasomotor symptoms associated with menopause among women in East Asia: a phase 3 randomized study (MOONLIGHT I). The Journal of international medical research. 2024.", "tier": "A", "kind": "rct", "pmid": "38818888", "doi": "10.1177/03000605241247684", "url": "https://pubmed.ncbi.nlm.nih.gov/38818888/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID38818888", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C50", "CSC1" ] }, { "n": 51, "citation": "Fraser GL, Lederman S, Waldbaum A et al. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause. Menopause (New York, N.Y.). 2020.", "tier": "A", "kind": "rct", "pmid": "32102086", "doi": "10.1097/GME.0000000000001510", "url": "https://pubmed.ncbi.nlm.nih.gov/32102086/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID32102086", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C51", "CSC1" ] }, { "n": 52, "citation": "Depypere H, Timmerman D, Donders G et al. Treatment of Menopausal Vasomotor Symptoms With Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a Trial. The Journal of clinical endocrinology and metabolism. 2019.", "tier": "A", "kind": "rct", "pmid": "31415087", "doi": "10.1210/jc.2019-00677", "url": "https://pubmed.ncbi.nlm.nih.gov/31415087/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID31415087", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C52", "CSC1" ] }, { "n": 53, "citation": "Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002.", "tier": "A", "kind": "rct", "pmid": "12117397", "doi": "10.1001/jama.288.3.321", "url": "https://pubmed.ncbi.nlm.nih.gov/12117397/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "WHI-EplusP", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C53", "CSC3" ] }, { "n": 54, "citation": "Anderson GL, Limacher M, Assaf AR et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004.", "tier": "A", "kind": "rct", "pmid": "15082697", "doi": "10.1001/jama.291.14.1701", "url": "https://pubmed.ncbi.nlm.nih.gov/15082697/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "WHI-CEEalone", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C54", "CSC3" ] }, { "n": 55, "citation": "Shumaker SA, Legault C, Rapp SR et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003.", "tier": "A", "kind": "rct", "pmid": "12771112", "doi": "10.1001/jama.289.20.2651", "url": "https://pubmed.ncbi.nlm.nih.gov/12771112/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "WHI-EplusP", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C55", "CSC3", "CH" ] }, { "n": 56, "citation": "Shumaker SA, Legault C, Kuller L et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004.", "tier": "A", "kind": "rct", "pmid": "15213206", "doi": "10.1001/jama.291.24.2947", "url": "https://pubmed.ncbi.nlm.nih.gov/15213206/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "WHI-CEEalone", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C56", "CSC3" ] }, { "n": 57, "citation": "Hodis HN, Mack WJ, Henderson VW et al. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. The New England journal of medicine. 2016.", "tier": "A", "kind": "rct", "pmid": "27028912", "doi": "10.1056/NEJMoa1505241", "url": "https://pubmed.ncbi.nlm.nih.gov/27028912/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "ELITE-NCT00114517", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 0:METHODS:paragraph0, 0:METHODS:paragraph2, 0:METHODS:paragraph5, 0:METHODS:paragraph6, 1:RESULTS:paragraph2, 1:RESULTS:paragraph3, 1:RESULTS:paragraph6. No complete-paper or supplement audit claimed.", "carries_claims": [ "C57", "CSC3" ] }, { "n": 58, "citation": "Henderson VW, St John JA, Hodis HN et al. Cognitive effects of estradiol after menopause: A randomized trial of the timing hypothesis. Neurology. 2016.", "tier": "A", "kind": "rct", "pmid": "27421538", "doi": "10.1212/WNL.0000000000002980", "url": "https://pubmed.ncbi.nlm.nih.gov/27421538/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "ELITE-NCT00114517", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C58", "CSC3" ] }, { "n": 59, "citation": "Gleason CE, Dowling NM, Wharton W et al. Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS-Cognitive and Affective Study. PLoS medicine. 2015.", "tier": "A", "kind": "rct", "pmid": "26035291", "doi": "10.1371/journal.pmed.1001833", "url": "https://pubmed.ncbi.nlm.nih.gov/26035291/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "KEEPS-NCT00154180", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph4, 1:Methods:paragraph6, 1:Methods:paragraph8, 1:Methods:paragraph22, 2:Results:paragraph1, 2:Results:paragraph4, 2:Results:paragraph12, 2:Results:paragraph14. No complete-paper or supplement audit claimed.", "carries_claims": [ "C59", "CSC2", "CSC3" ] }, { "n": 60, "citation": "Baik SH, Baye F, McDonald CJ. Use of menopausal hormone therapy beyond age 65 years and its effects on women's health outcomes by types, routes, and doses. Menopause (New York, N.Y.). 2024.", "tier": "A", "kind": "primary", "pmid": "38595196", "doi": "10.1097/GME.0000000000002335", "url": "https://pubmed.ncbi.nlm.nih.gov/38595196/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID38595196", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C60", "CSC3" ] }, { "n": 61, "citation": "Joffe H, Guthrie KA, LaCroix AZ et al. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. JAMA internal medicine. 2014.", "tier": "A", "kind": "rct", "pmid": "24861828", "doi": "10.1001/jamainternmed.2014.1891", "url": "https://pubmed.ncbi.nlm.nih.gov/24861828/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID24861828", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:METHODS:paragraph0, 1:METHODS:paragraph3, 1:METHODS:paragraph6, 1:METHODS:paragraph8, 2:RESULTS:paragraph1, 2:RESULTS:paragraph2, 2:RESULTS:paragraph3. No complete-paper or supplement audit claimed.", "carries_claims": [ "C61", "CSC2", "CH" ] }, { "n": 62, "citation": "Lobo RA, Archer DF, Kagan R et al. A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial. Obstetrics and gynecology. 2018.", "tier": "A", "kind": "rct", "pmid": "29889748", "doi": "10.1097/AOG.0000000000002645", "url": "https://pubmed.ncbi.nlm.nih.gov/29889748/", "status_flags": [ "ErratumIn: PMID30134411" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "REPLENISH-NCT01942668", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C62", "CSC2" ] }, { "n": 63, "citation": "Huang G, Basaria S, Travison TG et al. Testosterone dose-response relationships in hysterectomized women with or without oophorectomy: effects on sexual function, body composition, muscle performance and physical function in a randomized trial. Menopause (New York, N.Y.). 2014.", "tier": "A", "kind": "rct", "pmid": "24281237", "doi": "10.1097/GME.0000000000000093", "url": "https://pubmed.ncbi.nlm.nih.gov/24281237/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "Testosterone-dose-response-NCT00494208", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:METHODS:paragraph0, 1:METHODS:paragraph1, 1:METHODS:paragraph3, 1:METHODS:paragraph6, 1:METHODS:paragraph7, 2:RESULTS:paragraph3, 2:RESULTS:paragraph6, 2:RESULTS:paragraph7, 3:DISCUSSION:paragraph1, 3:DISCUSSION:paragraph4. No complete-paper or supplement audit claimed.", "carries_claims": [ "C63", "CSC5" ] }, { "n": 64, "citation": "Huang G, Tang E, Aakil A et al. Testosterone dose-response relationships with cardiovascular risk markers in androgen-deficient women: a randomized, placebo-controlled trial. The Journal of clinical endocrinology and metabolism. 2014.", "tier": "A", "kind": "rct", "pmid": "24712568", "doi": "10.1210/jc.2013-4160", "url": "https://pubmed.ncbi.nlm.nih.gov/24712568/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "Testosterone-dose-response-NCT00494208", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C64", "CSC5" ] } ], "independence_basis": { "required": true, "lines": [ { "label": "Blinded symptom-allocation trials", "sources": [ 61, 2, 62 ], "excludes_error": "Random allocation reduces treatment-selection and spontaneous-regression confounding; different hormone trials are replications of this line and share diary/expectancy risks." }, { "label": "Predicted thermoregulatory effect measured independently of symptom diaries", "sources": [ 36, 37 ], "excludes_error": "A prospectively tested sweating-threshold response with laboratory skin-conductance flushing is not manufactured by diary misreporting alone. Thermal challenge and a different measurement instrument narrow that specific error, while common hormone pharmacology and autonomic expectancy remain shared concerns." }, { "label": "Orthogonal downstream NKB challenge and NK3 blockade", "sources": [ 42, 43 ], "excludes_error": "A neuropeptide challenge and receptor antagonism reverse different pathway directions using objective and clinical endpoints. This supports SC1/M2 circuitry and narrows an exclusive expectancy account; it does not add an extra MHT efficacy trial to SC2." } ], "shared_failure_mode_checked": true, "note": "Ζ is not awarded for different sponsors, routes, sites or papers alone. The symptom RCT platform is one replicated pharmacological line; the instrument-independent thermal prediction addresses its diary-reporting failure mode, with induction/withdrawal only complementary because of uncontrolled exposure or unblinding. Downstream NKB challenge/blockade applies principally to SC1 and the nonhormonal model. WHI/WHIMS, REPLENISH, ELITE, testosterone dose-response and interview/extension reports share parent studies. Shared pharmacology, subjective endpoints and limited blinding-integrity measurement remain explicit limitations." }, "gamma_hard_rules_considered": [ { "subclaim_id": "SC1", "rule_quoted": "ROS change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC1", "rule_quoted": "NAD level change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC1", "rule_quoted": "Mitochondrial metrics alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC1", "rule_quoted": "Senescence marker changes alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC1", "rule_quoted": "Single-species or single-strain evidence", "trigger_status": "The lifespan-specific animal rule is explicitly adapted for direct human clinical trials; a symptom indication does not require extending lifespan or testing humans as multiple species." }, { "subclaim_id": "SC1", "rule_quoted": "Biomarker-only improvement without organismal benefit", "trigger_status": "Isolated hormone, lipid, bone or vascular-marker movement retains Γ for a hard clinical prevention/function inference; symptom or sexual-function outcomes are considered under their own indication." }, { "subclaim_id": "SC2", "rule_quoted": "ROS change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC2", "rule_quoted": "NAD level change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC2", "rule_quoted": "Mitochondrial metrics alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC2", "rule_quoted": "Senescence marker changes alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC2", "rule_quoted": "Single-species or single-strain evidence", "trigger_status": "The lifespan-specific animal rule is explicitly adapted for direct human clinical trials; a symptom indication does not require extending lifespan or testing humans as multiple species." }, { "subclaim_id": "SC2", "rule_quoted": "Biomarker-only improvement without organismal benefit", "trigger_status": "Isolated hormone, lipid, bone or vascular-marker movement retains Γ for a hard clinical prevention/function inference; symptom or sexual-function outcomes are considered under their own indication." }, { "subclaim_id": "SC3", "rule_quoted": "ROS change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC3", "rule_quoted": "NAD level change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC3", "rule_quoted": "Mitochondrial metrics alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC3", "rule_quoted": "Senescence marker changes alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC3", "rule_quoted": "Single-species or single-strain evidence", "trigger_status": "The lifespan-specific animal rule is explicitly adapted for direct human clinical trials; a symptom indication does not require extending lifespan or testing humans as multiple species." }, { "subclaim_id": "SC3", "rule_quoted": "Biomarker-only improvement without organismal benefit", "trigger_status": "Isolated hormone, lipid, bone or vascular-marker movement retains Γ for a hard clinical prevention/function inference; symptom or sexual-function outcomes are considered under their own indication." }, { "subclaim_id": "SC4", "rule_quoted": "ROS change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC4", "rule_quoted": "NAD level change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC4", "rule_quoted": "Mitochondrial metrics alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC4", "rule_quoted": "Senescence marker changes alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC4", "rule_quoted": "Single-species or single-strain evidence", "trigger_status": "The lifespan-specific animal rule is explicitly adapted for direct human clinical trials; a symptom indication does not require extending lifespan or testing humans as multiple species." }, { "subclaim_id": "SC4", "rule_quoted": "Biomarker-only improvement without organismal benefit", "trigger_status": "Isolated hormone, lipid, bone or vascular-marker movement retains Γ for a hard clinical prevention/function inference; symptom or sexual-function outcomes are considered under their own indication." }, { "subclaim_id": "SC5", "rule_quoted": "ROS change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC5", "rule_quoted": "NAD level change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC5", "rule_quoted": "Mitochondrial metrics alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC5", "rule_quoted": "Senescence marker changes alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC5", "rule_quoted": "Single-species or single-strain evidence", "trigger_status": "The lifespan-specific animal rule is explicitly adapted for direct human clinical trials; a symptom indication does not require extending lifespan or testing humans as multiple species." }, { "subclaim_id": "SC5", "rule_quoted": "Biomarker-only improvement without organismal benefit", "trigger_status": "Isolated hormone, lipid, bone or vascular-marker movement retains Γ for a hard clinical prevention/function inference; symptom or sexual-function outcomes are considered under their own indication." } ], "consensus_validation": { "completed": true, "status": "completed_original_source_reconciliation", "provider_mode": "Consensus Pro signed-in browser; observed output and citation link mappings", "queries": [ "https://consensus.app/search/menopause-hormone-treatment-efficacy/csofN1CBS4KZsu4h-esm7A/" ], "query_record_note": "Exact visible question/response retained privately in raw browser receipt.", "primary_comparison_count": 12, "primary_comparisons": [ { "pmid": "24861828", "doi": "10.1001/jamainternmed.2014.1891", "source_type": "primary study report", "study_group": "PMID24861828", "access_depth": "full_text_partial", "consensus_aspect": "MsFLASH endpoint and active comparison", "result_comparison": "Consensus correctly distinguishes estradiol and venlafaxine placebo contrasts from their imprecise direct comparison. Selected original Methods confirm baseline bothersome symptoms, identical pills, randomization and diary-defined primary frequency; Results show both active arms improve that endpoint. The small between-active difference does not prove broad hormone superiority.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/24861828/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\menopause-hormone-symptoms\\examinations\\original-52-61-5000.json" ], "body_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\menopause-hormone-symptoms\\body-presentation-receipts\\24861828-s1-p0-3-6-8.json", "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\menopause-hormone-symptoms\\body-presentation-receipts\\24861828-s2-p1-2-3.json" ] }, { "pmid": "29889748", "doi": "10.1097/AOG.0000000000002645", "source_type": "primary study report", "study_group": "REPLENISH-NCT01942668", "access_depth": "abstract_metadata", "consensus_aspect": "REPLENISH dose and endpoint hierarchy", "result_comparison": "Consensus identifies the right primary symptom and endometrial endpoints. The examined original abstract distinguishes dose-specific frequency and severity success and separates medication-exposed, endometrial-analysis and symptom-substudy populations. Its assertion that the endometrial analysis count simply represents completion is unsupported. The attached correction was identified; no universal zero-risk inference is used.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/29889748/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\menopause-hormone-symptoms\\examinations\\original-61-64-6000.json" ], "body_receipts": [] }, { "pmid": "29889748", "doi": "10.1097/AOG.0000000000002645", "source_type": "primary study report", "study_group": "REPLENISH-NCT01942668", "access_depth": "abstract_metadata", "consensus_aspect": "Blinding description and integrity", "result_comparison": "Consensus calls REPLENISH double-dummy blinding maintained. The examined original primary abstract establishes a randomized double-blind single-capsule trial, but does not document allocation-guess performance. A design label cannot verify actual maintained masking, and no invented double-dummy or blinding-integrity check is credited.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/29889748/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\menopause-hormone-symptoms\\examinations\\original-61-64-6000.json" ], "body_receipts": [] }, { "pmid": "40952729", "doi": "10.1001/jamainternmed.2025.4510", "source_type": "primary study report", "study_group": "WHI-two-parent-trials", "access_depth": "abstract_metadata", "consensus_aspect": "Corrected WHI secondary analysis and age scope", "result_comparison": "Consensus appropriately separates symptom benefit from prevention but relies heavily on this later WHI report. Its linked parent has two attached corrections concerning text/supplement and Figure 3. Correction identities were checked, while substantive details remain unavailable in the examined passages, so numerical subgroup claims are withheld. This report remains grouped with the original WHI parents rather than counted as a new independent trial.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/40952729/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\menopause-hormone-symptoms\\examinations\\original-8-16-5000.json" ], "body_receipts": [] }, { "pmid": "12771112", "doi": "10.1001/jama.289.20.2651", "source_type": "primary study report", "study_group": "WHI-EplusP", "access_depth": "abstract_metadata", "consensus_aspect": "Original WHIMS omitted by the automated date filter", "result_comparison": "The observed Consensus search applied a From2014 filter and did not provide the older WHIMS original requested. The independently examined original randomized report shows probable dementia increased with the tested combined regimen among women enrolled aged at least sixty-five. Its age/regimen scope is retained; this is neither proof all modern therapy has the same risk nor evidence of dementia prevention. Provider omission does not erase the original study.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/12771112/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\menopause-hormone-symptoms\\examinations\\original-52-61-5000.json" ], "body_receipts": [] }, { "pmid": "26035291", "doi": "10.1371/journal.pmed.1001833", "source_type": "primary study report", "study_group": "KEEPS-NCT00154180", "access_depth": "full_text_partial", "consensus_aspect": "KEEPS symptom versus cognitive outcomes and route claims", "result_comparison": "Consensus highlights KEEPS symptom relief and discusses transdermal superiority via a network meta-analysis. Selected KEEPS original Methods/Results show both hormone routes reduce symptoms, but cognition does not improve and mood effects differ by route. A network ranking or absent head-to-head superiority result cannot establish that transdermal hormone therapy is universally superior or prevents dementia.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/26035291/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\menopause-hormone-symptoms\\examinations\\original-52-61-5000.json" ], "body_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\menopause-hormone-symptoms\\body-presentation-receipts\\26035291-s1-p4-6-8-22.json", "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\menopause-hormone-symptoms\\body-presentation-receipts\\26035291-s2-p1-4-12-14.json" ] }, { "pmid": "18987368", "doi": "10.1056/NEJMoa0707302", "source_type": "primary study report", "study_group": "PMID18987368", "access_depth": "abstract_metadata", "consensus_aspect": "Testosterone HSDD versus nonspecific enhancement", "result_comparison": "The requested APHRODITE/INTIMATE distinctions were not substantively supplied in the filtered Consensus response. The examined APHRODITE original supports modest sexual-function benefit in baseline diagnosed HSDD at the tested higher patch dose, alongside dose and safety limits. The indication is not transferred to energy, cognition or muscle in all women.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/18987368/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\menopause-hormone-symptoms\\examinations\\original-16-24-5000.json" ], "body_receipts": [] }, { "pmid": "25430996", "doi": "10.1007/s40618-014-0213-3", "source_type": "primary study report", "study_group": "Testosterone-dose-response-NCT00494208", "access_depth": "full_text_partial", "consensus_aspect": "Testosterone cognition despite measured exposure", "result_comparison": "The observed Consensus response does not adjudicate the requested testosterone cognitive originals. Selected original Methods/Results of the dose-response trial document verified hormone exposure and no significant benefit across tested cognitive domains, with small complete-data groups. This bounds broad cognitive claims without declaring every dose/formulation ineffective.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/25430996/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\menopause-hormone-symptoms\\examinations\\original-32-40-5000.json" ], "body_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\menopause-hormone-symptoms\\body-presentation-receipts\\25430996-s1-p0-1-2-4.json", "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\menopause-hormone-symptoms\\body-presentation-receipts\\25430996-s2-p0-3.json" ] }, { "pmid": "24716847", "doi": "10.1111/cen.12459", "source_type": "primary study report", "study_group": "PMID24716847", "access_depth": "abstract_metadata", "consensus_aspect": "Positive narrow testosterone cognitive countercase", "result_comparison": "Independent primary examination preserves the randomized verbal-learning signal that a uniformly negative summary would omit. Other cognitive tasks and general wellbeing did not improve in the same trial. This is a bounded task result with a mapped domain boundary, not evidence of generalized brain protection.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/24716847/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\menopause-hormone-symptoms\\examinations\\original-24-32-5000.json" ], "body_receipts": [] }, { "pmid": "24281237", "doi": "10.1097/GME.0000000000000093", "source_type": "primary study report", "study_group": "Testosterone-dose-response-NCT00494208", "access_depth": "full_text_partial", "consensus_aspect": "Testosterone muscle exposure and function", "result_comparison": "The examined dose-response original finds selected muscle-power and lean-mass gains primarily at supraphysiologic exposure, while other physical-function tests did not improve. The same trial also supplies the cognitive and cardiometabolic-marker reports, so these papers are one parent study. A physiological-dose wellbeing claim cannot inherit high-exposure secondary muscle results.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/24281237/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\menopause-hormone-symptoms\\examinations\\original-61-64-6000.json" ], "body_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\menopause-hormone-symptoms\\body-presentation-receipts\\24281237-s1-p0-1-3-6-7.json", "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\menopause-hormone-symptoms\\body-presentation-receipts\\24281237-s2-p3-6-7.json", "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\menopause-hormone-symptoms\\body-presentation-receipts\\24281237-s3-p1-4.json" ] }, { "pmid": "40920404", "doi": "10.1001/jamainternmed.2025.4421", "source_type": "primary study report", "study_group": "PMID40920404", "access_depth": "full_text_partial", "consensus_aspect": "Contemporary nonhormonal efficacy and safety horizon", "result_comparison": "The provider discusses neurokinin alternatives, but the original OASIS3 Methods/Results verify a prespecified twelve-week primary symptom test and descriptive longer secondary outcomes with more treatment-related adverse events. That design supports a nonhormonal symptom pathway; it does not demonstrate cardiovascular prevention or lifetime safety.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/40920404/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\menopause-hormone-symptoms\\examinations\\original-40-46-5000.json" ], "body_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\menopause-hormone-symptoms\\body-presentation-receipts\\40920404-s1-p1-4-8.json", "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\menopause-hormone-symptoms\\body-presentation-receipts\\40920404-s2-p10-11-13.json" ] }, { "pmid": "11872200", "doi": "10.1016/s0015-0282(01)03009-6", "source_type": "primary study report", "study_group": "PMID11872200", "access_depth": "abstract_metadata", "consensus_aspect": "Older independently instrumented mechanism milestone", "result_comparison": "The automated provider date filter omitted the requested early thermoregulatory original. Its examined primary abstract describes randomized estradiol/placebo treatment with increased sweating threshold and reduced objectively recorded laboratory flushing. This narrows diary-only reporting bias, while its small sample and unisolated complete mediator chain remain limitations.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/11872200/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\menopause-hormone-symptoms\\examinations\\original-32-40-5000.json" ], "body_receipts": [] } ], "grade_changed": false, "grade_change_note": "Source-based adjudication; no independent blinded regrade claimed.", "raw_receipts": [ { "path": "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\menopause-hormone-symptoms\\consensus-browser-2026-10-12.json", "sha256": "4644225497279096a6b4e325834c42f75427823238d8c8e539cc8f463c566d01" } ], "independent_blinded_audit": false, "cutoff": "2026-10-12", "completed_utc": "2026-10-13T06:25:00.676296+00:00", "conclusion": "Endpoint hierarchy, experimental scope and original-source limits determine the evidence cards; provider wording does not override them." } }